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resumo 
 
 
A investigação em engenharia de tecidos (ET) tem procurado soluções para as necessidades de reforço 
e de regeneração dos tecidos recorrendo por vezes a substâncias bioactivas que podem favorecer a 
proliferação celular. Os avanços recentes em ET têm beneficiado da utilização de matrizes 
tridimensionais porosas (scaffolds) que permitem a adesão, proliferação e regeneração das células bem 
como a vascularização, estimulando a formação de novo tecido. A obtenção de scaffolds de quitosano 
(CH) para a regeneração óssea tem merecido especial interesse devido às suas propriedades biológicas 
e físicas, apresentando no entanto o inconveniente da falta de resistência mecânica e de bioatividade. A 
obtenção de scaffolds compósitos por incorporação na matriz polimérica de materiais bioactivos de 
fosfato de cálcio, permite reforçar o scaffold, melhorando o seu desempenho mecânico e a sua 
osteocondutividade.  
No presente trabalho, produziram-se scaffolds compósitos de quitosano/hidroxiapatite por processos de 
congelamento e liofilização de suspensões de fosfatos de cálcio (CaP) em soluções de CH. Utilizaram-
se CaP sintetizados laboratorialmente, quer na forma de fibras de hidroxiapatite (HA), quer de lamelas 
de monetite, quer de mistura dos dois. Os CaP foram sintetizados por um método de precipitação em 
meio aquoso, tendo-se monitorizado a precipitação de fosfato de cálcio durante 3 dias. Avaliou-se a 
evolução das fases cristalinas e da morfologia das partículas precipitadas por microscopia eletrónica de 
varrimento (SEM), difracção de raios X (XRD) e por adsorção de N2 usando a isotérmica de BET. Os 
resultados evidenciaram que o aumento da temperatura de refluxo acelera a transformação das fibras 
de octacalcium fosfato em fibras de HÁ, permitindo reduzir o tempo de precipitação total para 
obtenção de fibras de HA 
 As soluções de quitosano e as suspensões de HAP em solução de CH, a dois valores de pH (pH=2 e 
pH= 5), foram congeladas a três temperaturas diferentes antes de serem liofilizadas. Caracterizaram-se 
os scaffolds por SEM, DRX, microtomografia computorizada (µ-CT) e espectroscopia de 
infravermelhos com transformada de Fourier (FTIR), tendo-se ainda avaliado o seu comportamento 
mecânico em compressão. Obtiveram-se scaffolds compósitos macroporosos com porosidade superior 
a 80%, tamanho de poro na gama 50-250µm e porosidade interconectada com grau de interconexão de 
91-98.5%. Verificou-se que o tamanho e morfologia de poro dos scaffolds é condicionado pelo pH das 
suspensões e pela temperatura de congelamento. O valor de pH mais elevado (pH=5) e a temperatura 
de congelamento mais elevada (T=0ºC) são as condições que mais favorecem o crescimento de cristais 
de gelo e por conseguinte a formação de poros de maior dimensão. Verificou-se também que a 
incorporação de partículas de CaP na matriz polimérica de CH aumenta a resistência mecânica do 
scaffold, que é também condicionada pelo tamanho de poro e pela morfologia da partícula de CaP. O 
estudo do comportamento bioactivo dos scaffolds compósitos em soluções simuladoras do plasma 
humano (SBF), monitorizando a variação das concentrações de Ca e P na solução de SBF, evidenciou 
o contributo das partículas de CaP para a bioactividade do scaffold. Os scaffolds compósitos em que 
coexistem brushite e HA (preparados a pH=2) evidenciaram bioactividade superior á dos scaffolds 
compósitos CH/HA. 
Preparam-se também scaffolds incorporando grânulos de hidroxiapatite carregados com um fármaco 
modelo, a dexametasona (DEX), na solução inicial de CH. Os grânulos obtiveram-se por atomização 
de suspensões de HA nanométrica em solução de DEX. Construíram-se os perfis de libertação da DEX 
em solução tampão fosfato (PBS) por determinação da concentração de DEX por espectroscopia de 
ultravioleta (UV) ao comprimento de onda de 242 nm. Entre as várias curvas de libertação de DEX 
decorrentes das diferentes metodologias testadas para carregamento do fármaco, evidenciou-se um 
perfil de libertação de DEX segundo o qual cerca de 80% da DEX é libertado ao longo de ~30 dias, 
assegurando-se assim uma libertação mais lenta e prolongada do que as referidas na literatura para a 
DEX  
As características dos scaffolds compósitos preparados no presente trabalho apontam os materiais 
produzidos como promissores para aplicação em engenharia de tecidos, apresentando como potencial 
adicional a capacidade de se comportarem como sistemas de libertação controlada de fármacos. 
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abstract 
 
Tissue engineering research attempts to satisfy the needs of support, reinforcement and in some 
cases organization of the regenerating tissue with a controlled supply of bioactive substances that 
might positively influence the behaviour of incorporated or ingrowing cells. As demonstrated by the 
recent advances on biomaterials, the ideal scaffold for tissue regeneration should offer a 3D 
interconnected porous structure behaving as a template to promote cells adhesion and proliferation 
and vascularisation as well thus stimulating the new tissue ingrowth. A special interest has been 
focused on chitosan (CH - the partially deacetylated derivative of chitin) scaffolds for bone 
regeneration due to its biological and physical properties, in spite of some drawbacks regarding its 
lack of mechanical strength and bioactivity. The incorporation of bioactive calcium phosphates 
materials in the polymer matrix is expected to reinforce chitosan scaffolds improving their 
mechanical performance and osteoconductivity. 
In the present work, chitosan based scaffolds were produced by freeze-drying CH solutions 
containing calcium phosphate (CaP) particles, either as fibers of hydroxyapatite (HA), platelets of 
monetite or a mixture of both. CaP particles were prepared by a wet precipitation method. The 
calcium phosphate precipitation was monitored by taking a number of samples during 3-days. 
Evolution of the morphology and crystal phase composition of the precipitated particles were 
followed by scanning electron microscopy (SEM), N2 adsorption using the BET isotherm (BET), and 
X-ray diffraction (XRD). It was observed that the increase of refluxing temperature allowed a faster 
transformation of octacalcium phosphate fibers into HA fibers, hence shortening the precipitation 
time required for obtaining HA fibers, 
Chitosan based scaffolds suspensions at two different pH values were frozen at three different 
temperatures before freeze-drying (thermally induced phase separation-TIPS). SEM, XRD, 
microcomputed tomography (µ-CT) and Fourier transformed infrared spectroscopy (FTIR) were used 
to analyze the physical and chemical properties of the composite scaffolds. Compressive mechanical 
tests were also undertaken to characterize the materials. Bioactivity studies were performed in 
simulated body fluid (SBF) solutions by monitoring the Ca and P concentration variations of SBF 
solutions.  
Highly interconnected macroporous scaffolds with a pore size ranging from of 50 to 250µm, 
interconnectivity around 91-98.5%, and porosity higher than 80% were obtained. The freezing 
temperature and the pH of chitosan solution/suspension revealed to play a significant influence in the 
pore structure. The higher pH (pH=5) and the higher freezing temperature (T=0ºC) were found as the 
most favourable conditions for ice crystal growth which resulted in larger pores. It was also observed 
that CaP particles incorporation in the CH matrix increased the scaffold mechanical strength which 
was also conditioned by the pore size and by the reinforcing particle morphology. The bioactivity 
studies revealed the CaP contribution for the scaffold bioactivity. The composite scaffolds having 
brushite and HA (obtained at pH=2) exhibited enhanced bioactivity as compared to composite 
CH/HA scaffolds based.  
CH based scaffolds were also prepared by incorporating HA granules loaded with dexamethasone 
(DEX), a drug model, in CH solution. The granules were obtained by spray drying HA nanosized 
particles suspended in DEX solution. The drug release profiles of DEX were determined in 
phosphate-buffered solution (PBS) by DEX concentration evaluation in the releasing medium by 
Ultraviolet (UV) spectroscopy at the wavelength of 242 nm. Among the different DEX release 
patterns corresponding to the various DEX loading methodologies which were tested, an adequate 
release profile could be selected: it showed that the release of 80% of the DEX loaded amount could 
be ensured during ~30 days, thus enabling a prolonged and slowest DEX release as compared to 
literature reports. It is thus found that the CH scaffolds engineered with a calcium phosphate based 
drug delivery system (DDS) provides the desirable association of a bioactive and osteoconductive 
matrix with an in situ controlled release of a therapeutic agent. These results point out an additional 
potential of the composite CH/HA scaffolds for behaving as a controlled drug release system (DDS).   
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GLOSSARY 
 
Biomineralization : The process by which living organisms produce minerals, 
often to harden or stiffen existing tissues 
In vitro : Refers to study in experimental biology in which take place 
in glass/plastic container in the laboratory (outside the 
living body)  
In vivo : Refers to study in experimental biology in the living 
organism (opposite of in vitro) 
Lyzozome : Enzyme responsible for breaking down the polysaccharide 
walls of many kinds of bacteria and thus it provides some 
protection against infection; also degrade chitosan. 
Osteoblast : Mononucleate cells which are responsible for bone 
formation 
Osteogenesis : A process of new bone materials deposition which is done 
by osteoblasts 
Osteoconductivity : The ability of a material to support osteoblastic cells 
adhesion, growth, and differentiation 
Vascularization : The formation of new blood vessels in tissues 
Proliferation  : The growth and reproduction of similar cells. 
Chapter 1: Introduction 
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Chapter 1  
Introduction & Objectives 
 
Tissue engineering (TE) is an important therapeutic strategy aiming at replacing 
and facilitating the re-growth of injured or diseased tissue1. The application of tissue 
engineering comprises in a wide range area, such as fabricated skin, liver, pancreas, 
cartilage, bone, ligament, tendon, etc2. Its basic concept started believing that cells can be 
isolated from a patient, expanded in a culture, seeded into a carrier, and finally grafted 
back into the patient. The goal of tissue engineering which is to fabricate living 
replacement parts for the body is achieved by combining three main elements: biomaterials 
(scaffold), cells, and bioactive/signaling molecules3.   
One of tissue engineering applications is bone regeneration. Bone loss due to 
trauma or disease is one vital health problem. In United States at least 6,3 million fractures 
happen every year, bone problem due to osteoporosis harm over 10 million Americans, 
and disease due to low bone mass affect another 34 millions3. In all those cases and also 
other cases, such as bone cancers, bone regeneration is critical in order to restore the 
function. 
Several medical treatments are available for bone injuries, being autograft one of 
them. In the case of autograft, implantation is done by harvesting bone tissue from one 
certain site in patient’s body and fixing it to the injured site. However, several limitations 
were found in these treatments, such as loosing function in the place where the bone was 
harvested, infection, and pain. Besides autograft, allograft and xenograft can also be done 
for bone implantation where the bone grafts are obtained from another person and another 
species, respectively. In this case, spreading of danger diseases and negative response from 
the body might occur3. Bone implantation can also be done by using metallic materials, 
such as iron, cobalt, titanium. Nevertheless, some drawbacks mainly related to the 
inappropriate mechanical properties appear. Ceramic materials are also able to be utilized 
for surgical implantations. However, besides their inadequate mechanical performance, 
several shortcomings from both ceramics and metals are their low or non-biodegradability 
and limited processing.  
The development in TE area might be one of the solutions of the previous 
problems. By utilizing scaffolds, cells, and or bioactive molecules to support and facilitate 
the growth of new bone tissue, a bone defect will be restored without the use of any 
permanent implant3. TE approach in general, including for bone regeneration, can be done 
in several ways as shown in Figure 1-1. Based on the existence of cells prior to 
implantation, systems can be divided into two: cellular systems and acellular systems4. In 
acellular systems, scaffolds are implanted directly in the human body without cell addition. 
While in cellular system, two approaches can be done: (1) seeding cell at point of delivery 
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and (2) seeding and allowing cells to remodel the scaffold into natural tissue in the 
laboratory prior to implantation5. 
 
Figure 1-1 Application of scaffolds in tissue engineering (TE) approach consisting of (1) in vivo 
approaches with or without cells and (2) traditional TE which involves seeding and growing cells in the 
laboratory 5 
 
Based on explanation above, it is clear that the scaffold has an important role in TE 
approach. In order to fulfill its purpose, the scaffold has to meet several requirements, such 
as: biocompatibility, bioactivity, biodegradability, and appropriate mechanical properties. 
Several materials, including ceramics, polymer, and ceramics-polymer composite have 
been used for preparing scaffolds. The advantages of using ceramics, such as CaP 
(Hydroxyapatite/HA, β-Tricalcium phosphate/β-TCP) and bioglass, are their 
biocompatibility, osteoconductivity and sufficient mechanical strength. HA is one 
compound which is most used since its chemical composition is similar with inorganic 
component of bone in human body. In the other hand, they also have several shortcomings, 
such as being slowly degradable and brittle6. Utilizing polymers have some limitations, 
mainly poor stiffness and compression strength. As compared to ceramics, some polymers, 
such as polylactid acid (PLA, PLLA, PDLA), polyglycolic acid (PGA), collagen, alginate, 
and chitosan, may easily degrade. The adequate combination of ceramics and polymers is 
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thus being addressed as a promising approach for producing scaffolds displaying the 
desired characteristic for bone TE. 
 Another function of the scaffold in bone regeneration besides its supporting 
structure role for cells grow is as drug delivery system (DDS). During its function as cell 
growth support, ideal scaffolds are supposed to degrade6, 26, 7. Based on this nature, drugs 
can be loaded into the scaffold and later released to implantation sites during scaffold 
degradation.  
Among the most studied composite scaffold, it is worthy to mention chitosan/CaP 
(CH/CaP) composite materials due to chitosan biocompatibility and biodegradability and 
to bioactivity of CaP (as HA and TCP). A number of studies on the area of CH/CaP has 
been carried out8, 9, 10, 11, 7, 43 showing that the addition of CaP has improved the 
mechanical properties of CH/β-TCP scaffold9, the biocompatibility and bioactivity of 
CH/nano-HA scaffold8, 43 . Furthermore it was also shown that CH scaffold may play a 
retarding role during a drug release, i.e. gentamincin sulphate, which is kept under release 
for more than 3 weeks7, thus pointing its potential for DDS applications. However the 
combination of scaffold and DDS performance in the same biomaterial device has been 
scarcely exploited.  Furthermore CH based scaffolds still present relatively modest pore 
sizes, very often less than 100µm8, 43. Studies aiming to improve CH scaffolds 
microstructure are thus still welcome.  
In the framework of the CH issues stated above, it is necessary to further exploit 
both the composition and the manufacturing method of CH/HA composite scaffold in 
order to improve its structural characteristics (including pore size, porosity, 
interconnectivity) and potentialities as a DDS. The present study is thus targeted to the 
development of CH/HA composite scaffolds aimed at bone regeneration, with the 
following objectives: 
1. To exploit and understand the role of processing variables including the pH of chitosan 
solution, and the freezing temperature on chitosan based scaffolds microstructure. 
2. To combine the effects of processing variables  and of  different types of CaP 
reinforcing particles for engineering the scaffold microstructure and bioactivity while  
improving the mechanical properties of the scaffold 
3. To evaluate the potentiality of CH scaffolds as drug delivery system. 
For achieving these objectives, composite scaffolds with different compositions 
were produced under different experimental freeze drying conditions. The microstructure, 
mechanical properties, and bioactivity of the obtained scaffolds are here analyzed and 
discussed. Furthermore, the scaffolds behavior as drug delivery systems using 
dexamethasone as a drug model is also analyzed.   
This report consists of five chapters. Chapter 1 addresses the interest and objectives 
of the present study. In Chapter 2, literature review about scaffolds, including its 
requirements, raw materials and manufacturing techniques are set up to build up better 
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understanding on this area. The problem formulation of this research is presented in 
Chapter 3. Materials and methods of the experimental procedure are explained in Chapter 
4. The results and respective discussions are presented in Chapter 5. Finally the main 
conclusions and recommendations are summarized in Chapters 6. 
 
Chapter 2: Literature Review 
 
 
5 
 
Chapter 2  
Literature Review 
 
In the following section, basic knowledge and information regarding to the topic 
from recent publications and books are presented in order to have better understanding. In 
section 2.1 a number of issues related to porous scaffold requirements for bone 
regeneration are explained. Section 2.2 describes the material choices for scaffold; 
information about chitosan and CaP are written here. And in section 2.3, a number of 
scaffold manufacturing processes are illustrated. 
 
2.1. Porous Scaffold for Bone Regeneration 
In tissue engineering, scaffold has an important role. Scaffold is designed as three-
dimensional biodegradable structure which possesses a high porosity and pore 
interconnectivity. It performs as structural support for cells while they gradually degrade 
and the new tissue being formed6.  
As mentioned in chapter 1 about scaffold requirements, the criteria for choosing 
materials to perform as scaffold are quite complicated and challenging since it has to face 
complex biological and sensitive system as the human body. In the case of bone 
regeneration application, several requirements should be fulfilled as shown in Table 2-1. 
 
Table 2-1 Scaffold Basic Design Parameters for Bone Tissue Engineering12 
Parameter Requirements 
Porosity  Maximum possible without compromising mechanical properties (typical 
porosity around 90%) 
Pore size 200-400µm 
Pore structure  Interconnected 
Mechanical properties of cancellous bone  
Tension and compression Strength : 5-10 MPa 
 Modulus : 50-100 MPa 
Mechanical properties of cotical bone  
Tension Strength : 80-150 MPa 
 Modulus 17-20 GPa 
Compression Strength : 130-220 MPa 
 Modulus : 17-20 GPa 
 Fracture Toughness : 6-8MPa √m 
Degradation Properties  
Degradation time Must be tailored to match the application in patients 
Degradation mechanism Bulk dissolution in medium 
Biocompatibility No chronic inflammation 
Sterizability Strerizable without altering material properties 
Bioactivity Bioactive 
 
Basically, mechanical properties of scaffold should match with the tissue at the 
implantation sites and provide the correct stress environment for the neotissues2,6. 
Biocompatibility is needed; in which generation of any unwanted tissue response to the 
implant is avoided so that not inflammatory response occurs3. In the case of 
biodegradability, scaffold is required to degrade in a controlled manner to facilitate load 
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transfer to develop bone and allow bone growth into the defect. Furthermore, it is 
compulsory for the degradation products to be non-toxic to the body3. High interconnected 
porosity structure and high surface area are needed to allow cell adhesion, proliferation, 
facilitating cell contacts, and cell migration in order to encourage bone ingrowths and 
repair1,2 
Osteoconductive materials are preferable, in which the properties of a material 
show an ability to support bone growth by providing a site for cell attachment and vascular 
ingrowth3. Another requirement is bioactivity; bioactive materials allow and enhance the 
formation of apatitic layer which allow bonding to the bone tissue. 
 
2.1.1. Mechanical Properties 
In the case of mechanical properties, porous scaffold materials should match with 
the properties of target sites. It should be able to give enough strength to the damaged 
locations and in the same time allow gradual load transfer in order to facilitate the newly 
growth tissue for bone recovery3.  
Bone has very unique mechanical properties which are originated from its chemical 
components and hierarchical organization13, 14, 15. As shown in Figure 2-1, bone is a 
complex biological material which consists of collagen fibril and HA crystal. Inorganic 
material which is mainly HA covers 60% composition of bone, organic material covers 
30%, and the remaining 10% is water. This composition makes bone with outstanding 
mechanical properties in which the compressive strength is originated from the rigid HA, 
while collagen fibrils are capable of energy dissipation and impart the tensile properties3. 
 
 
Figure 2-1 Hierarchically structured biological material in which the building components are 
precisely arranged at scales (left)13. Nanocomposite consisting of crystal HA and collagen fibril in bone 
(right)15  
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Two types of bone exist in human body, i.e. cortical bone and cancellous bone. 
Cortical bone which covers 80% of adult skeleton is hard, compact, dense bone which 
posses only 10% porosity3. Its strength values are 79-151MPa in tension and 131-224MPa 
in compression; its modulus is 17-20GPa in both compression and tension. Cancellous 
bone on the other hand is spongy and may have 50-90% porosity. Its compressive strength 
is 4-12MPa and its modulus is 0.1-0.5GPa13.  
Figure 2-2 shows a comparison of mechanical properties between several polymer 
and ceramic-based biomaterials with natural bone. It is shown that dense biodegradable 
polymer has close mechanical properties with cancellous bone, and dense bioactive 
ceramics with cortical bone21. However, when it comes to porous materials, mechanical 
properties of both porous biodegradable polymer and porous bioactive ceramics need to be 
improved. By combining the two materials: ceramics and polymer; porous biodegradable 
composites are able to improve the mechanical properties closer to cancellous bone. 
 
Figure 2-2 Mechanical properties (both compressive strength and elastic modulus) of biodegradable 
polymer, bioactive ceramics and composite21 
 
A huge number of materials including the class of synthetic polymers (PLA, PGA, 
PCL, PPF), natural polymers (chitosan, collagen), bioactive ceramics, bioactive glass, and 
polymer-ceramic composite21 have been investigated to imitate the properties of bone. In 
the area of porous biodegradable composite, numerous researches have been done; for 
instance amorphous CaP, HA, Bioglass were used to reinforce PLGA, PLLA, and PLA21, 
chitosan9,10,11, and collagen16. Boccaccini and Maquet achieved three times higher 
compressive modulus of PLGA by addition of 50%wt of bioglass17, Zhang and Zhang9  
were able to improve compressive modulus of chitosan from 0.967 to 2.191 MPa and the 
yield strength from 0.109 to 0.208 MPa with reinforcement of β-TCP. 
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2.1.2. Scaffold Morphology 
Control of scaffold morphology is very crucial for its application in tissue 
engineering since it influences its degradation kinetics, mechanical properties, and also 
controls the cellular colonization rates and organization within an engineered tissue18.  
High porosity and critical pore size are essential. High interconnected porosity is 
needed to facilitate diffusion of nutrients and waste (degraded materials); it also supports 
the vascularization of ingrown tissue. A typical porosity of 90% is obligatory for good 
vascularization and cell penetration. Large surface area is needed for cell attachment and 
growth; while large pore volume is required to facilitate sufficient place for tissue repair. A 
certain pore size is necessary to be fulfilled depending on the type of applications; in the 
case of bone optimum size should be in the range of 100-350µm, 20-125µm for adult 
mammalian skin, 5-15 for fiberblast ingrowth, etc2. 
Table 2-2 illustrates the pore size and porosity dependence of bone regeneration 
development as summarized by Yang et al.2. It is known that porosity is one important 
variable for bone regeneration after one research which shows that there was no new bone 
formed on the solid particle, while in porous scaffold direct osteogeneis occurred19. 
However, it is not only porosity which influence bone growth as shown in Table 2-2, but 
also pore size. One material with porosity of 33.5% with very small pore (2-6µm) shows 
no tissue ingrowth. 
In the point of view of pore size, from Table 2-2, research from Klawitter et al.19  
which implanted calcium aluminate cylindrical pellet to dog femorals showed that pore 
size of ~100µm is typical minimum pore for bone regeneration. Data provided by Whang 
et al.20 shows that higher pore size (<350µm) showed significant bone growth, however 
this data is not complete since unavailability of the pore distribution. On contradiction to 
Klawitter et al., one research with titanium plates which were implanted to rabbit femorals 
defects under non-load-bearing showed that all pore sizes (50, 75, 100, and 125 µm) 
indicated no significant differences in the ingrowth bone19. These suggested that ~100 µm 
may not be the critical pore for non-load-bearing applications. Whang et al.20 also 
succeeded to prove another method of bone growth via hematoma stabilization. In this 
case, scaffold with porosity of 90% and pore size in the range of 16-32 µm are capable of 
osteoinduction to grow new bone.  
   From those descriptions, minimum pore size for bone regeneration may not be 
~100 µm for some cases: such as non-load bearing conditions and another mechanism of 
bone growth based on hematoma stabilization. However, it is suggested to have at least 
100 µm in order to allow proper cell penetration and vascularization of the ingrown 
tissue2,21. Furthermore, pore size bigger than 300 µm is recommended due to enhance new 
bone formation while small pores favored hypoxic conditions in which there is a lack of 
oxygen and ultimately can cause bone diseases19. 
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Table 2-2 Studies defining optimal pore size for bone regeneration2 
 
 
Figure 2-3 shows several typical morphologies of porous scaffold which are 
produced with different manufacturing techniques. Figure 2-3-a shows one typical 3-D 
porous scaffold with interconnected open pore prepared with freeze drying or particulate 
leaching. Different structural types are also available; such as in nanofibrous matrix 
(Figure 2-3-b) and microsphere (Figure 2-3-c). Each type is produced with different 
techniques and also can be used for different application. Nanofiber mesh type is usually 
produced by fiber bonding method. Microsphere scaffold can be used with injection 
method. Further information about scaffold manufacturing methods will be presented in 
section 2.2.  
 
 
Figure 2-3 Different forms of polymeric scaffolds for tissue engineering: (A) a typical 3-D porous 
matrix in the form of a solid foam, (B) a nanofibrous matrix, (C) porous microsphere50 
 
 2.1.3. Scaffold Bioactivity
Implant materials which are placed in th
encapsulated by fibrous tissue and become isolated from the surrounded bone
tendency depends much on type of materials; for instance, in chitosan based materials, this 
occurrence is minimal to happen
adherence of implant materials and surrounding bone are crucial
materials encapsulation should be avoided furthermore bonding with the surrounding
tissue should be enhanced. This phen
called bioactivity. 
Bioactivity is the ability of materials to stimulate the growth of apatite layer on
surface when placed in human body. This apatite layer normally consists of nano
of carbonate-ion-containing apatite that has a defective structure and low crystallinity. This 
biological active carbonate HA layer is chemically and structurally
mineral phase in bone. Due to this similarity, bone producing cells, i.e., osteoblasts, can 
preferentially proliferate on the apatite, and differentiate to form an extracellular matrix 
composed of biological apatite and collagen
surrounding bone comes into direct contact wit
to the artificial materials. 
 
Figure 2-4 (a) TEM photograph illustrating the apatite layer in
W and a rat tibia - 8 weeks after implantation
 
Some materials are known to be bioactive, such as: bioactive glass (contains SiO
Na2O, CaO, and P2O5) like, for instance,
24,5% NaO, 24,4% CaO, and 
components, such as CaO and P
addition or layer of bioactive materials are needed to improve their properties.
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In vitro formation of apatite layer can be promoted by immersing tested materials 
in SBF (simulated body fluid). SBF is a fluid prepared with ion concentration equal to 
those of the human blood plasma; as shown in Table 2-3.  
 
Table 2-3 Nominal ion concentrations of SBF in comparison with those in human blood plasma24 
Ion Ion Concentration 
Blood Plasma SBF 
Na+ 
K+ 
Mg2+ 
Ca2+ 
Cl- 
HCO3- 
HPO42- 
SO42- 
pH 
142.0 
5.0 
1.5 
2.5 
103.0 
27.0 
1.0 
0.5 
7.2-7.4 
142.0 
5.0 
1.5 
2.5 
147.8 
4.2 
1.0 
0.5 
7.40 
 
2.1.4. Scaffold Biodegradability 
In most cases, implanted scaffolds are supposed to degrade prior to the insertion to 
the body. Instance or partially degradation is expected to occur while the tissues or organs 
remodel and grow1, 25. In the view point of TE applications, understanding of degradation 
mechanism is crucial. How these materials degrade, how long time is needed to degrade, 
and what is the degradation product need to be studied prior to its application in human 
body. Tunable degradation time and non-toxic waste of degradation are urgent in TE 
applications. Toxic waste of degradation process might trigger the occurrence of 
inflammatory response 
Ceramic and metal materials are known to have limited and non biodegradability. 
On the contrary, most of polymers are biodegradable2. Basically, there are two main 
mechanisms of polymer materials degradation in vivo: enzymatic and non-enzymatic 
degradation process. Synthetic polymer such as PLA, PGA, PLLA degrades through non-
enzymatic degradation which involves de-esterification process21. One issue which 
addresses to synthetic polymer degradation is the possibility of strong inflammation to 
occur if the acidic degradation product is released abruptly. On the contrary of synthetic 
polymers; natural polymers degrade mainly by enzymatic process; for example chitosan 
which degrade through hydrolysis of acetylated residues by lysozyme1. 
Biodegradation time of scaffolds is supposed to be able to be tuned easily 
depending on its certain application. By combining ceramics with polymers, for instance, 
one can tailor the degradation time of the produced scaffold. Boccaccini et al.17 succeeded 
to retard the degradation time of PLGA by addition of bioglass.  
A wide range of degradation time depending on type of materials is available. 
PLGA basically degrades too quickly in which they lost 50% of their tensile strength 
during two weeks; while PGA degrades too slowly where 3-6 years are needed for 
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complete resorption1. Others example are poly(propylene fumarate) or PPF in which lose 
about 13.6-27.9% of their weight during 12 hours in PBS immersion; poly(glycolide-co-
caprolactone) or PGCL lose 50% mass during 6 weeks25.    
 
2.1.5. Scaffold as Drug Delivery System 
Basically, human body has the ability of initiating tissue regeneration after injury, 
such as in bone marrow and skin. However, this ability varies much depending on size and 
cause of injury, and also on the age of each individual. In this case, having drug which can 
support and stimulate the regeneration process will be advantageous. Scaffold which can 
combine synergies of the porous support structure and of the drug delivery for promoting 
bone tissue regeneration may be envisaged the solution for this challenge.  
 
Figure 2-5 Schematic illustration of the most common strategies to fabricate DDS in 3-D scaffold: 
drugs adsorption either in their unprotected (a) or protected (b) forms and drug entrapment either in 
their unprotected (c) or protected (d) forms 6 
 
Delivery system has been applied in several therapies, such as: delivery of insulin, 
anticancer, anti-inflammatory agents, growth factors, etc26. Regarding to bone 
regeneration, several bioactive molecules and/or drugs can be loaded into the carriers (i.e. 
scaffold): (1) biomolecules or also known as growth factors 14, 27, 28  such as BMP/bone 
morphogenetic protein, EGF/epidermal growth factor, PDGF/platelet-derived growth 
factor, TGF-β1/transforming growth factor-beta1, FGF/fibroblast growth factors, 
VEGF/vascular endothelial growth factor, (2) antibiotics such as gentamicin, tetracycline, 
ciprofloxacin, polymiyxin B and (3) anti-inflammatory drug such as dexamethasone, 
ibuprofen6.  
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Several types of carriers have been used in drug delivery, such as nanoparticles, 
microspheres, membranes, rods, hydrogels and also 3D scaffolds28, 29. In the case of 
scaffolds, the drugs can be loaded into the scaffold by using several techniques, as shown 
in Figure 2-5. The drugs can be adsorbed or entrapped and also protected (with 
microspheres) or unprotected. Furthermore, the preparation method also influences 
whether the drug release is dominated by diffusion or degradation of the matrix.  
Ideally the drugs are delivered locally into the injured sites in controlled release 
manner which allows an adequate concentration level to be built up in a certain desired 
time. This is the benefit of having controlled drug delivery system, offering a tailored drug 
release pattern. Without controlled release, the drug might be released quickly thus 
enabling the possibility of the entire drug amount to be supplied before the infection stop.  
The materials which have been used as drug delivery are varied, from polymers to 
inorganic materials28. The polymers which can be applied as drug delivery systems can be 
divided into two main groups: (a) natural polymers, including alginate, chitosan, and 
collagen; and (b) synthetic polymers, including polyesters, polyaminoamides, 
polyacrylates, and their copolymers and blends. All these biodegradable materials degrade 
during its application while releasing the loaded-drug. 
 
2.2. Scaffold Materials Choices 
 
Basically, there are three main types of materials which can be used to prepare 
scaffolds, i.e. polymers, ceramics, and composites.  
Both natural and synthetic polymers have been used in tissue engineering 
applications. Natural polymers; such as collagen, gelatin, chitin, chitosan, alginate, 
cellulose, starch14, 33 have been widely applied. However poor mechanical performance of 
some of them limits their usage. Synthetic polymers, belonging mainly to the 
polylactic/polyglycolic acid group, have been in use for more than 20 years in surgical 
sutures2.  
A wide range of ceramics has been employed in biomedical applications. In the 
field of bone regeneration, HA-based CaP compounds and bioactive glass have been the 
most widely used due to their bioactivity and osteoconductivity properties. 
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Table 2-4 Summary of Scaffold Materials Choices12 
Biomaterials Positive Negative 
Ceramics   
CaP (e.g. HA, triCaP, and biphasic 
CaP) 
1. Excellent biocompatibility 
2. Supporting cell activity 
3. Good osteoconductivity 
1. Too fragile in amorphous 
structure 
2. Nearly bioinert in crystalline 
structure 
Bioactive glass and glass-ceramics 
(e.g. bioglass, apatite-wollastonite, 
ceravital) 
1. Excellent biocompatibility 
2. Supporting cell activity 
3. Good osteoconductivity 
4. Vascularization 
5. Tailorable degradation rate 
1. Mechanically brittle and weak 
in glass state 
2. Degrade slowly at crystalline 
structure 
Synthetic Polymer   
Biodegradable polymer 
(poly(lactic acid)/PLA, 
poly(glycolic acid)/PGA, 
poly(propylene fumarate)/PPF) 
1. Good biocompatibility 
2. Bioresorbable 
3. Good processability 
4. Good ductility 
1. Inflammation caused by acid 
degradation product 
2. Accelerated degradation rates 
cause collapse of scaffold 
   
Surface bioerodible polymer 
(poly(ortho esters)/POE, 
poly(anhydrides), 
poly(phosphazane)/PPHOS) 
1. Good biocompatibility 1. They cannot be completely 
replaced by new bone tissue 
Natural Polymer   
Polysaccharides (alginate, 
chitosan) 
1. Good biocompatibility 
2. Good Biodegradability 
1. Mechanically weak 
Protein (collagen, fibrin)   
Composites 1. Excellent biocompatibility 
2. Supporting cell activity 
3. Good osteoconductivity 
4. Tailorable degradation rate 
5. Improved mechanical 
properties 
Fabrication techniques can be 
complex 
 
2.2.1. Chitosan 
 
Naturally derived polymers are of special interest mainly due to their degradability, 
biocompatibility, low cost, and availability30. Besides, as natural component of living 
structures, their biological and chemical similarities to natural tissues are also the reasons 
why they are used abundantly in TE1.  
Basically, there are two main classes of natural origin polymers which have been 
widely used: protein-based polymers and polysaccharide or carbohydrate-based 
polymers33,30. Protein-based polymers, such as collagen, gelatin, and fibrin, have the 
advantage of mimicking many features of extracellular matrix and thus have the potential 
to promote better cell migration, growth, and organization during tissue regeneration30. 
Polysaccharide class such as chitosan, alginate, hyaluronan, and starch, have very good 
compatibility with blood (haemocompatibility properties) which might be due to their 
chemical similarities with heparin (component of blood)14, 30.  
Chitosan is a linear polysaccharide, derived from chitin by (partial) deacetylation of 
chitin in the solid state under alkaline condition (NaOH concentrated) or by enzymatic 
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hydrolysis in the presence of chitin deacetylase31. It is composed of glucosamine and N-
acetyl glucosamine units linked by β (1-4) glucosidic bonds1. The structure of both 
chitosan and chitin can be seen in Figure 2-6. Chitin is the second most abundant polymer 
after cellulose. It can be obtained from exoskeleton of arthropods, such as shrimp, and also 
from the cell walls of fungi and yeast31. The properties of chitin and chitosan such as 
biocompatibilty and nontoxicity make them important materials in biomedical 
applications.   
Chitosan can be used in the form of gel sponge, membrane, bead, and porous scaffold. 
Its easy processability by dissolving it in acid solution (pH < 6), makes chitosan become 
one of the most used materials in biomedical applications. The practical use of chitosan 
has been developed recently by modification to improve its solubility or to introduce 
desired properties. The main chemical modifications applied to chitosan work based on 
graft copolymerization and chemical grafting32, 1. Some examples of modified chitosan 
applications are: (1) specific recognition of cell can be introduced to chitosan by sugar 
modification; such as galactosylated chitosan for hepatocyte attachment, (2) sialic acid 
bounded chitosan to inhibit influenza1, (3) ethylene diamine tetraacetic acid (EDTA) 
grafted onto chitosan increases the antibacterial activity of chitosan32, etc. Furthermore, 
functional biomaterials made from chitosan have been used in wide range of applications, 
such as tissue engineering (both cartilage and bone), wound dressing, drug delivery, and 
cancer diagnosis31. 
 
 
Figure 2-6 Structure of Chitin and Chitosan31 
 
The illustration of chitosan applications in tissue engineering field is shown in Figure 
2-7. Chitosan can be processed with cells and combined also with other biomaterials (such 
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as bioceramics: CaP; and other polymers like gelatin). Chitosan scaffolds for tissue 
engineering application are mainly produced by lyophilization, as can be seen in Figure 
2-7. Despite all advantages of using chitosan as mentioned above, several drawbacks of 
using chitosan are found, such as their poor mechanical properties and absence of 
bioactivity. In order to overcome these problems and obtain better properties, 
reinforcement with inorganic bioactive particles might be one of the solutions. 
 
 
Figure 2-7 Illustrations of selected examples of chitosan scaffold processing in tissue engineering (from 
left to right): (1) in situ gelling, (2) lyophilization, (3) wet spinning, (4) and (5) lyophilization of mixture 
of chitosan solution and calcium phosphate and other polymer (gelatin)23 
 
2.2.2. Calcium Phosphates 
 
An extensive variety of ceramics has been utilized in the area of medical applications 
due to their positive interactions with human body, such as: CaPs, silica, alumina, zirconia, 
and titanium dioxide. The characteristics of these ceramics are usually high mechanical 
strength, good-body response, and low or non-existing biodegradability33. One type of 
ceramics which have been used widely is calcium phosphate (CaP), mainly class of 
calcium orthophosphate34 which naturally exist as the main compounds of bone and teeth.  
Among wide range of CaP compounds (as shown in Table 2-5), HA is one type of 
ceramics which is applied most in bone tissue field since around 60% of bone is made 
from HA21, 35. HA have an outstanding biocompatibility due to their close chemical and 
crystal resemblance to bone mineral. Besides HA, β-TCP and BCP (mixture between TCP 
and HA) are also used extensively.  
In the point of view of biodegradability, β-TCP degrades faster than HA. However, 
when it is pHA (precipitates HA which contains smaller crystallites size) compared to 
sintered HA, the biodegradation is strongly enhanced due to higher solubility36. Regarding 
the mechanical properties, it depends on several factors: porosity, composition, 
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microstructure, and flaws/reliability16. Increase in pore size and porosity lead to lower 
mechanical strength. In the point of view of composition, one study shows that in BCP, 
increasing the amount of β-TCP resulted in lower mechanical strength16. Regarding 
biological response, these CaP compounds might also behave differently. Kruyt et al. 
investigated the bone ingrowth of HA, BCP, and β-TCP by addition of BMSC (bone 
marrow stromal cells). The results show that bone ingrowth was better in BCP and β-TCP 
compared to HA33.  
 
Table 2-5 Abbreviations of CaP-compounds with corresponding chemical formula and Ca/P-ratio33 
Abbreviat
ion 
Name Formula Ca/P-Ratio 
ACP Amorphous Calcium Phosphate - 1.25<x<1.55 
BCP Biphasic Calcium Phosphate Ca3(PO4)2+Ca10(PO4)6(OH)2 1.50<x<1.67 
CA Carbonated apatite, dahlite Ca5(PO4,CO3)3 1.67 
CDHA Calcium deficient Hydroxyapatite Ca10-x(HPO4)x(PO4)6-x(OH)2-x 1.50<x<1.67 
DCPA Dicalcium Phosphate anhydrous, 
Monetite 
CaHPO4 1.00 
DCPD Dicalcium Phosphate dihydrate, Brushite CaHPO4.H2O 1.00 
HA Hydroxyapatite Ca10(PO4)6(OH)2 1.67 
MCPM Monocalcium Phosphate monohydrate Ca(H2PO4)6.H2O 0.50 
OCP Octacalcium Phosphate Ca8H2(PO4)6.5H2O 1.33 
pHA Precipitated Hydroxyapatite Ca10-x(HPO4)x(PO4)6-x(OH)2-x 1.50<x<1.67 
α-TCP α-Tricalcium Phosphate, Whitlockite α-Ca3(PO4)2 1.50 
β-TCP β-Tricalcium Phosphate, Whitlockite β-Ca3(PO4)2 1.50 
TTCP Tetracalcium Phosphate, Hilgenstockite CaO.Ca3(PO4)2 2.00 
 
CaP compounds can be used in the form of granules, cement (granules with 
phosphate salt and water), and 3D scaffold. The type of 3D scaffold employed can be non-
porous or porous as can be seen in Figure 2-8. However, a number of drawbacks are found 
when using ceramics scaffold, such as: slow degradability and too brittle mechanical 
properties. 
 
Figure 2-8 Typical ceramic 3D-structure prepared by 3D printing : a. contain only macroporous; b. 
contain both macroporous & micropores33 
HA Fibers Precipitations 
Besides 3D scaffold, as mentioned before, CaP compound can be used in the form 
of granules and cement. Furthermore, these days, CaP fibers or whiskers are used to 
improve mechanical properties of ceramic matrix. For these purposes, HA crystal 
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preparation has been investigated extensively. Basically, there are two main methods to 
synthesize HA powders: (1) dry chemical method which include solid-state reaction and 
(2) wet chemical method which include hydrothermal reaction, precipitation, and 
hydrolysis methods37. By varying the synthesis route, HA particles may display different 
morphologies (shape and size) as can be seen in Figure 2-9. Plate-shaped apatites can be 
synthesized by the hydrothermal process using an organic medium. Spherical and fibre-
shaped apatites were prepared by ultrasonic spray-pyrolysis, by homogenous precipitation 
method, by solid state synthesis at high temperature and by sol-gel process56, 38. 
 
Figure 2-9 Various types of HA morphologies13  
One popular way to prepare HA crystals is homogenous precipitation. It is claimed 
to be an easy way to obtain uniform HA particles39 and tailor the morphologies38. It was 
found that additives can define the final precipitates. The additives can be organic solvents 
(acetone, methanol, ethanol, buthanol, ethylene glycol, and glycerin) and cations (Na+, K+, 
Mg2+, Sr2+, Ba2+, Al3+, and Y3+). The final crystal can be spherical or fiber-like depending 
on the additives38.  
Zhang et al.39 and Aizawa et al.56 succeeded to produce HA fibers with uniform 
morphology and good crystalinity. A mixture of 0,167 mol/L calcium ions and 0,1 mol/L 
phosphate ions were refluxed in a certain temperature. Ca(NO3)2 was used as the source of 
calcium; (NH4)2HPO4 as the source of phosphate; and urea as additive. Zhang et.al studied 
different synthetic temperature and time (120h at 85oC, 72h at 90oC, and 48h at 95oC), 
while Aizawa et.al 56 used 24h at 80oC and followed by 72h at 90oC. It is temperature, 
synthetic time, pH of the solution, concentration of Ca2+ and PO43- which become the main 
factor to influence the HA morphology. 
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Hydroxyapatite precipitation process may not be a straightforward process since 
different types of CaP solid phases may precipitate depending on the precipitating medium 
composition and pH. The formation of HA follows a multistep route which includes solid-
solid transformations13, 40. The CaP phases involved are: dicalcium phosphate anhydrate 
(DCPA) or monetite, octacalcium phosphate (OCP) and hydroxapatite (HA). The 
precipitation of any phase requires supersaturation conditions, being the solubility of each 
phase a pH dependent parameter. At pH 2.22-5.92, the precipitation order is usually: 
HA>>OCP>>Monetite39.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-10 Solubility isotherms of calcium phosphate phases in the ternary system of Ca(OH)2-H3P04-
KN03-H2O at 37 C41. The most important CaP compounds may form and subsequently dissolve 
depending on the solubility depending on this curve 
2.2.3. Chitosan/CaP Composite 
 
Combining polymers with ceramics to produce composite scaffold have became 
one very interesting research approach. Polymer scaffolds have poor mechanical properties 
and furthermore in the case of chitosan, lack of bioactivity. Conversely, ceramics scaffolds 
are too brittle and less biodegradable than polymers. Thus composite scaffolds combining 
these two kinds of materials are expected to present better properties. One problem may 
arise from composite scaffold manufacturing is as this process might be complex. 
A number of researches have been carried out on the topic of chitosan/CaP 
scaffold. Different phases of CaP were used to prepare scaffold; β-TCP7,9,10; nano-HA42, 43, 
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and some references used a mixture of CaP invert glasses (consists of CaO, P2O5, TiO2 and 
Na2O)7,10. Not only variation of the inorganic part, some researches were carried out using 
chitosan/HA and combination of other polymers, such as gelatin44,45 and alginate46. 
Thermally induced phase separation (TIPS) which involves freezing and freeze 
drying is the manufacturing technique mainly used to prepare chitosan/CaP scaffold. 
Composite scaffolds of chitosan and β-TCP, HA, and invert glass were prepared by 
addition of CaP powder to a chitosan solution (normally in acetic acid). The solution was 
put in a container/mold which afterward determines the shape of the scaffold. Instead of 
using mold, Ang et al.47 used a robotic desktop rapid prototyping to fabricate the scaffold. 
The next step prior to both methods is similar which are freezing and subsequently freeze-
drying.   
Composite scaffold of chitosan/nano-HA were prepared by two methods: (1) 
addition of Ca(NO3)2 and (NH4)2HPO4 to a chitosan solution; and nano-HA (140-260nm) 
was formed during the process8; this process is called in situ and (2) addition of nano HA 
powder42. Chitosan/β-TCP was prepared by adding directly the powder to chitosan 
solution prior to freezing.  
It was reported that several properties were improved by combining chitosan and 
CaP. Regarding the mechanical properties, Zhang et al.10 succeeded to increase the 
mechanical properties of chitosan scaffolds by addition of β-TCP. The adjustment of the 
type and the amount of the reinforcement enable the production of scaffolds with different 
microstruture morphology, mechanical properties, and degradation rates too. 
Not only mechanical properties, biocompatibility and bioactivity of chitosan/CaP 
composite scaffold were also improved. Bioactivity test by immersing composite scaffolds 
on SBF showed (1) mass increase of the chitosan/nHA scaffold which means apatite layer 
were formed8 and (2) concentration decrease of the Ca and P concentrations in SBF 
solution after immersion of chitosan/β-TCP composite scaffold10. Biocompatibility study 
by seeding pre-osteoblasts MC3T3-E142,8 and human osteoblast-like MG6348, shows 
higher population of cell on composite scaffold of chitosan/nHA. This means that 
composite scaffolds have superior cytocompatibility. 
 
2.3. Scaffold Manufacturing Techniques 
 
Various manufacturing techniques have been reported to produce polymer 
composite scaffolds, such as TIPS, solvent casting/particle leaching, solid free-form 
fabrication, microsphere sintering, scaffold coating, fiber bonding, high pressure 
processing, hydrocarbon templating, electrospinning, microsphere sintering, and melt 
molding, etc2, 14, 21. Among those manufacturing techniques, solvent casting with or 
without particle leaching and TIPS combined with freeze-drying are two very popular 
methods for preparing polymer composite scaffold.  
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2.3.1. Overview on scaffold manufacturing method 
 
Solvent casting/particulate leaching and TIPS are two methods that require the raw 
materials to be soluble in order to be processed. Solvent casting procedure involves the 
casting of a polymer/salt/organic mixture solution followed by solvent evaporation and 
removal of the salt by dissolution50. In solvent casting (as shown in Figure 2-11), the 
polymer solution is poured into a bed of porogen (the porogen can be salt particles, 
paraffin microspheres or emulsion drops of defined size). To evaporate the solvent, freeze 
drying can be applied. The porogen removal can be achieved by rinsing with distilled 
water or with an organic solvent2. In this way, the pore size can be tailored by the size of 
the porogen and the porosity can be tailored by ratio of the polymer and the amount of 
porogen49. However, two main limitations on using solvent casting are harmful solvents 
and limited thickness of porous scaffold (film) can be produced. 
 
 
Figure 2-11 Illustration on scaffold manufacturing using particle leaching method50 
 
TIPS is one very popular technique to fabricate 3D porous scaffold with high 
volume of interconnected micropores. In TIPS, the polymer is dissolved in a certain 
solvent. Liquid-liquid or solid-liquid phase separation is induced by lowering the 
temperature. The solvent is then sublimated and leaves a porous polymer scaffold2, 21. The 
limitations of this process are the following: quite long time is needed to sublimate the 
solvent completely, and shrinkage issues are also a concern. 
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Figure 2-12 Typical morphologies of porous scaffold made by different methods: (a) thermally induced 
phase separation, (b) solvent casting and particle leaching, (c) solid-free-from techniques, (d) 
microsphere sintering, and (e) cancellous bone21 
 
Table 2-6 Scaffold Manufacturing Techniques List50 
Fabrication 
Technology 
Required 
properties 
Available pore 
size (µm) 
Porosity 
(%) 
Architecture 
Solvent casting 
/particle leaching 
Soluble 30-300 20-50 Spherical pores 
TIPS Soluble <200 <97 High volume of 
interconnected pores 
Melt molding Thermoplastic 50-500 <80 Spherical pore 
Gas foaming Amorphous <100 10-30 High volume of 
noninterconnected pore 
Fused deposition 
modeling 
Thermoplastic >150 <80 100% interconnected 
macropores 
3-D printing Soluble 45-150 <60 100% interconnected 
macropores 
 
For thermoplastic polymer that cannot be dissolved, melt molding, and solid free 
form fabrication (SFF) techniques can be used. SFF also known as rapid prototyping are 
computerized fabrication techniques using data generated by CAD systems, computer-
based medical imaging modalities, digitizers and other data makers. Several types of SFF 
are Solid Laser Sintering (SLS), Three-Dimensional Printing (3-DP), and Fused 
Deposition Modeling (FDM)51. The advantage of using SFF is the ability of tailoring 
porous structures and the good interface with medical imaging.  
There are still some other techniques available, such as fiber bonding, membrane 
lamination, melt molding, hydrocarbon templating, etc. Figure 2-12 shows a typical 
porous polymer scaffold produced by different methods. Table 2-6 summarizes 
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information on polymer scaffolds fabrication techniques. It is clear that by using different 
materials, different methods, and also by controlling the variable in each manufacturing 
technique, the morphology of the scaffold can be tailored depending on the requirements. 
 
2.3.2. Thermally Induced Phase Separation (TIPS) 
 
Among the wide range of methods for preparing scaffolds, chitosan-based scaffolds 
have been mostly prepared by TIPS7,43. This probably reflects the easy preparation of 
chitosan solutions by dissolving chitosan in dilute acid.  
TIPS works based on the principle that a single homogenous polymer solution 
prepared at higher temperature is converted via the removal of thermal energy to two-
phase separated domains composed of a polymer-rich phase and a polymer-lean phase52. 
The removal of thermal energy is done by lowering the multicomponent system so that it 
becomes thermodynamically unstable and tends to separate into more than one phase in 
order to lower the system free energy49. After fully frozen, lyophilization/freeze drying is 
applied to sublimate the solvent-rich phase and leave a porous polymer scaffold. The pore 
morphology is controlled by any phase transition that occurs during the cooling process54 
i.e. solid-liquid phase separation or liquid-liquid separation. 
Basically there are two types of TIPS: solid-liquid phase separation and liquid-
liquid phase separation. In solid-liquid phase separation, lowering the temperature induce 
solvent crystallization from polymer solution; also define as solid formation in liquid 
phase49. Example of solid-liquid phase separation is the separation of chitosan-acetic acid 
solution; ice of acetic acid solution are formed and separated from chitosan-rich phase. 
Decreasing temperature can induce liquid-liquid phase separation in the case of a polymer 
solution with an upper critical solution temperature49. An example of this case is a mixture 
of dioxane and water which have been used to fabricate PLA & PLGA scaffold52. 
However, combination of both separation types can also be used. Lim et al.53 prepared 
porous chitosan scaffold from chitosan-acetic acid solution with alcohol as the non-
solvent.  
Figure 2-13 illustrates a binary phase diagram of polymer solution undergo three 
different cooling route. Depending on where the end point of quenching is located, 
whether (1) metastable region between binodal and spinodal curve or (2) unstable region 
below the spinodal curve, two distinctive morphologies can be achieved: (1) poorly 
interconnected bead-like structure by nucleation and growth mechanism or (2) well-
interconnected open pore structure52. Several parameters in TIPS influence the final 
morphologies (pore size distribution and interconnectivity) of porous scaffold: polymer 
concentration, quenching rate, and composition of solvent/non solvent52, 54.  
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Figure 2-13 Schematic phase diagram illustrating several possibility of morphology depending on 
cooling route54 
  
After the occurrence of phase separation during the cooling process, the frozen 
solution is freeze dried (or also known as lyophilized), i.e. the solvent is removed at very 
low pressure and temperature. Such conditions allow a phase change in which the frozen 
solvent (i.e. water) is converted in gas, i.e. a sublimation process. 55  
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Chapter 3  
Problem Formulation 
 
In the present work, a systematic study of chitosan based composite scaffolds is 
carried out. Pure chitosan and composite chitosan scaffolds using different reinforcing 
particles (HA fibers, monetite platelets and mixture of fibers and platelets) and HA 
granules loaded with drug) were prepared under different experimental conditions (pH of 
chitosan solution and freezing temperature). 
The HA fibers used to reinforce the scaffolds were prepared by a precipitation 
method. In this research, two routes combining different time and temperature (4h-80oC 
followed by 24h-90oC and 24h-80oC followed by 24h-90oC)  were applied. The chemical 
and crystal phase composition and the morphology of the precipitated particles were 
studied. 
Regarding chitosan based scaffolds, some experimental parameters were varied in 
order to obtain better microstructure, mechanical properties, and bioactivity of the 
resulting scaffolds. During the preparation of CH solution/suspension, the pH of the 
solution and the type of reinforcement particles were varied. Two pH values were used: pH 
2 and pH 5. The reinforcement particles with different shape and composition were 
obtained by precipitation:  HA-fibers, incipient monetite thin platelets and a mixture 
between those two types of particles. Furthermore, during TIPS, different freezing 
temperatures (0, -15, and -196oC (liquid N2)) were also used. The effects of these variables 
on scaffold microstructure, mechanical properties, and bioactivity were analyzed and 
investigated.  
For exploiting the potentiality of chitosan scaffolds as a drug delivery system 
(DDS), dexamethasone (DEX) was selected as a model drug. HA was also selected as a 
primary drug carrier. HA granules loaded with DEX were independently produced by 
spray drying HA nanoparticles suspended in a DEX solution. The spray dried HA granules 
loaded with DEX where then suspended in chitosan solution and subsequently freeze 
dried. Three different routes for preparing the drug loaded scaffold were adopted and their 
drug release profiles were studied. 
 
  
This research is divided in three main parts
precipitation method, preparation of 
scaffold and drug-loaded chitosan composite scaffold
from part one was used to reinforce chitosan scaffold
HA granules prepared by spray
described in Figure 4-1.  
 
Figure 4-1 Scheme of experimental done: HA fibers precipitation and its chitosan composite (left) and 
HA granules preparation and its chitosan composite (right)
4.1. Materials  
 
The materials which were used in 
hydrogenphosphate, >98%, ACS reagent from Aldrich Chemistry, Germany; (2) calcium 
nitrate-4-hydrate, analytical reagent from Riedel
urea ((NH2)2CO) from Sigma
Carlo Erba, Portugal. 
For CaPC composite scaffold 
crab shells, deacetylation degree approximately 80%, 
Chemistry (viscosity > 200.000 cps). Germany; (
Merck, Germany; (3) ethanol 96% from AGA, Portugal; (4) ammonia solution 2
Riedel-de Haen, Germany. The reagents used in the preparation of
listed in Table 4-3.  
Precipitation (section 4.2.1) and characterization 
of HA fibers (section 4.3.1
Preparation of CaPC composite scaffold
(section 4.2.2
Characterization (section 4.3.2
chemical composition; morphology; mechanical 
properties; and biactivity test in SBF
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Experimental Procedure 
: synthesis of CaP particles
CaPC (calcium phosphate-chitosan) 
s. The CaP precipitates obtained 
s. While for drug-loaded scaffold, 
-drying were used. The overall scheme of thi
 
 
CaP synthesis experiment are: (1)
-de Haen, Sigma-Aldrich. Germany; (3) 
-Aldrich, Germany; and (4) HNO3 65%, for analysis from 
preparation, the materials used are (1) chitosan, from 
practical grade fro
2) acetic acid 96%, pro analysis
 SBF test 
) 
)
) :
Preparation of HA and HA-DEX 
spray-drying76(previously prepared in 
Laboratory)
Preparation of drug-loaded CH composite 
scaffold
(section 4.2.3)
Characterization (section 4.3.3
chemical composition; morphology;  and drug 
release test in PBS
 
 
 by 
composite 
s research is 
 ammonium 
m Aldrich 
 from 
5% from 
solution are 
granules by 
) :
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In vitro release studies of drug-loaded CH composite scaffold experiments, the 
following reagents were used: (1) HA Suspension (5% HAp Nanoparticles) from 
Fluidinova, nanoXIM, Portugal; (2) dexamethasone 96% from ACROS organics, USA; (3) 
Na2HPO4.2H2O from Carlo Erba, Milano; and (4) NaH2PO4.H2O from Merck, Germany. 
 
4.2. Preparation Methods 
 
4.2.1. Precipitation of HA Fibers  
HA fibers were prepared by a precipitation method in aqueous solution, following a 
procedure described by Aizawa et al.56. A solution of 0,167M Ca(NO3)2, 0,100M 
(NH4)2HPO4, 0,50 M (NH2)2CO (urea) and 0,1M HNO3 was refluxed for a certain time at 
80oC and 90oC.  
Table 4-1 Raw Materials for HA Fiber Synthesize 
Composition Raw Material for 250 mL solution 
Ca(NO3)2 0,167 M Ca(NO3)2.2H2O 9,85 g 
(NH4)2HPO4 0,100 M (NH4)2HPO4 3,30 g 
(NH2)2CO 0,50 M (NH2)2CO 7,50 g 
HNO3 0,10 M HNO3 65% 1,73 mL 
 
The first experiment (so called batch 1) was carried out by refluxing (Figure 4-2-a) 
the solution for 24h at 80oC, followed by aging at 90oC for 72h. The second experiment 
(so called batch 2) was done by refluxing the solution for 4h at 80oC followed by aging at 
90oC for 72h. 
 Small amounts of the suspension were withdrawn in the middle of the refluxing 
process in order to follow the phase evolution. This procedure involved mixing and 
shaking the container to make sure that the suspension is uniformly sampled, and then 
pouring a little amount to a beaker, filtering in vacuum filter (Figure 4-2-b), washing the 
solid cake with distilled water, and drying it in the oven at 60oC. During the refluxing 
process, the pH of the solution was monitored and revealing an increasing from ~1 to ~7,5 
since NH3 was released by the hydrolysis of urea56.  
For batch 1, samplings were carried out at 0,5h, 1h, 2h, 4h, 8h, 20h, and 24h at 
80oC; followed by 24h, 48h, and 72h at 90oC. For batch 2, samplings were performed at 2h 
and 4h at 80oC; followed by 24h, 48h, and 72h at 90oC. All the obtained dried powders 
were analysed by X-Ray Diffraction (XRD), N2 adsorption using the BET isotherm (BET), 
and Scanning Electron Microscopy (SEM) to characterize the powder crystal phase 
composition and morphology. 
 Figure 4-2 (a) Reflux apparatus : round glass container equipped with cooling column immersed in 
waterbath; (b) vacuum filter with water
 
4.2.2. CH/CH Composite Scaffold Preparation
 
The main steps of the chitosan scaffold preparation are shown in 
Starting from chitosan solution, the next step was freezing to let the solvent solidify, 
subsequently followed by freeze
scaffold. 
 
Figure 4-3 Scheme of C
 
 
Preparation of CaPC Composite Solution in Acetic Acid 
Freezing : Solid
Freeze Drying/Lyophilization (Sublimation of solvent)
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-drying to sublimate the solvent and obtain the porous 
aPC composite scaffold preparation 
(Variation of pH & type of reinforcement)
-Liquid Phase Separation (Variation of 
Freezing Temperature)
Post-treatment with Ethanol
 
 
 
Figure 4-3. 
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Preparation of Chitosan solution/suspension 
2 wt% chitosan solutions were prepared with two different pH values, i.e. pH ~2 
and pH ~5. The chitosan solution at pH ~2 was prepared by dissolving 2g of chitosan in 
98g acetic acid 2M (pH =2.5-2.6; further these scaffolds are referred with scaffolds pH 2). 
The mixture was magnetic stirred at 50oC for 3-4 hours until complete dissolution. 
Chitosan solution at pH ~5 was prepared by weighing 2g of chitosan powder, adding (1) 
~70mL of distilled water, (2) acetic acid 25% drop by drop while stirring at 50oC until 
complete dissolution (pH ~3,5), and (3) ammonia (ammonia 25% : H2O = 2:1) drop by 
drop until pH ~5 was reached. Finally, distilled water was added until the total mass 100 g 
of the solution. 
 
 
Figure 4-4 (a) Chitosan Solution Preparation with Magnetic Stirer; (b) and (c) Differently shaped 
containers used for preparing the chitosan-based scaffolds   
 
The composite scaffolds were prepared with a (chitosan:calcium phosphate) ratio 
of (2:1) by weight. Following the same procedure as described above, before adding the 
distilled water to 100g of the total mass, 1 gram of calcium phosphate (hydroxyapatite 
fibers which was obtained via precipitation method (4h 80oC+24h 90oC), monetite powder 
(30min of reflux), mixture of HA fibers & monetite powder and spray dried-HA granules 
with or without DEX) were then added to the solution. The resulting suspension was then 
stirred for 1 to several hours in order to homogenize. Ten minutes of sonication were also 
allowed in order to ensure a complete mixing. Finally, the chitosan solution or the 
chitosan/calcium phosphate suspension were poured into a container (a mold which 
determines the final 3D shape of the scaffold) being then ready to be frozen. 
Three different freezing temperature were used in this experiment, i.e. ~0oC , -15oC 
and -196oC (liquid N2). The freezing process at ~0oC and -15oC were carried out during 
24h. Quenching in liquid N2 was carried out very rapidly, being the container directly 
immersed in liquid N2 for ~4min. After freezing and quenching procedures, the solidified 
chitosan solution/suspension was quickly transferred to the freeze-dryer. 
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Freeze-Drying/Lyophilization 
Frozen chitosan solution/suspensions were placed in a freeze-dryer as illustrated in 
Figure 4-5-a. Freeze drying (also known as lyophilization) is a process aiming to remove 
the solvent through a sublimation process. Labconco Freeze Dry System (operating at 
~52oC and 12x10-3 mbar) was used in this experiment. In order to reach complete 
sublimation of the solvent, 3 days of freeze-drying were applied to all the samples. 
Particular attention was paid to ensure that a constant pressure is required; increase of 
pressure will not allow phase transformation from ice to water vapor directly but from ice 
to liquid water. If this occurs in the beginning of lyophilization, the samples might be 
damaged, since chitosan (in the presence of acetic) might dissolve.  
 
 
Figure 4-5 (a) Frezee-drying apparatus; (b) and (c) Various shape of CH/CH composite scaffold after 
freeze-dried 
 
Postprocessing with Ethanol 
Freeze-dried samples were rehydrated and stabilized with ethanol treatment 
following the procedure by Madihally et al.18 with modifications in order to remove the 
acetic which still existing in the scaffold. This treatment is needed in order to avoid 
moisture uptake by the scaffold.  
The first treatment was done by immersing the scaffold in absolute alcohol (99%) 
for 1 hour, followed by 30minutes in 70% ethanol and another 30minutes in 50% ethanol. 
After immersion in ethanol, the samples were subsequently quenched in liquid N2 and 
placed again in freeze-drying for 24h.  
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4.2.3. Drug-Loaded Composite Scaffold 
Drug-loaded composite scaffold was prepared with the same procedure as CH 
composite scaffold (as written in section 4.2.2) in which drug-loaded HA granules were 
used instead of fiber to reinforce chitosan. Pure HA granules and drug-loaded HA granules 
were produced by spray-drying of HA and HA-drug suspension76. In this study, 
dexamethasone (DEX, Figure 4-6) as one anti-inflammatory drug was used as drug model 
and spray-dried with HA suspension in the proportion of 10%wt (DEX/HA). 
 
Figure 4-6 Chemical Structure of Dexamethasone80 
 Different procedures were used in the preparation of CH composite solution 
containing drug-loaded HA granules: (1) pure HA granules and DEX were added to CH 
solution (pH ~5), (2) drug-loaded HA granules were added to CH solution (pH ~5) without 
any additional DEX, and (3) additional DEX was added to CH composite solution 
prepared with the second procedure (Table 4-2) 
 
Table 4-2 CH Composite Scaffold Solution/Suspension Composition for DDS 
 Procedure 1 Procedure 2 Procedure 3 
2%wt CH solution 10 g 10 g 10 g 
HA granules 100 mg pure HA 
granules 
100 mg spray dried 
HA-DEX granules 
100 mg spray dried 
HA-DEX granules 
Additional DEX - - 10 mg 
  
CH composite solutions were magnetic-stirred and ultra-sonicated in order to 
prepare an homogenous solution. The solution was put in a mold (Figure 4-5-c) and 
subsequently put in the freezer (0oC) for 24h. Frozen solution was then freeze-dried for 
70h to sublimate all the solvent.  
 
4.3. Characterization 
4.3.1. Precipitation of HA Fibers  
Characterization of the as synthesized calcium phosphate powder was carried out 
by several methods, including: X-Ray diffraction (XRD), N2 adsorption with the BET 
Chapter 4: Experimental Procedure 
 
 
32 
 
isotherm, and Scanning Electron Microscopy (SEM). XRD was performed in order to 
identify the powder crystal phase composition. This test was carried out in a equipment 
Rigaku Geigerflex DMAX III/C using monochromatic CuKα (1.54056 Å) radiation at 
40kV. The 2θ scan range was 3-80o with the scanning speed 3o/min.  
Relationship between shape of peaks in XRD spectra and crystallite size is 
explained by The Scherrer equation57. The peak broadening can be observed when 
crystallite size is smaller than 100Å. Smaller crystallite size and more random oriented 
crystal will have broader diffraction peaks. Scherrer equation is written in equation 4.1. 
 () =
. ∝
 ∙ 
 
(4.1) 
 =
(2 − 2)
180
∙ 	 
(4.2) 
where α is x-ray wavelength (1.54Å in this case); c is a factor depending on crystal shape 
(usually in the range of 0.9-1; 0.9 is taken); B is the difference in angles at half of 
maximum intensity or also called full width at half max (FWHM; which is calculated 
based on equation 4.2); and θ is the Bragg angle in radian57. Monetite crystallites size were 
measured based on peak (002), OCP based on peak (010), and HA based on peak (300). 
In order to calculate the relative amount of each phase in one sample, the area 
below each peak was calculated. For crystallite size calculation, the same peak area of 
monetite were measured based on peak (002) at 2θ=~26.5o, OCP based on peak (010) at 
2θ=~4.6o, and HA based on peak (300) 2θ=~32.5o. 
The surface area of the powder was accessed by N2 adsorption at 200oC with the 
BET isotherm in equipment from Micromeritics Gemini. 
The powder morphology was evaluated by scanning electron microscopy Hitachi 
SE-70 SEM. The powder samples were dispersed on the sample holder with the help of 
carbon-tape and then coated with a conductive layer of gold-palladium and finally 
observed in SEM at 15kV using different magnifications. 
 
4.3.2. CH/CH Composite Scaffold 
 
X-Ray Diffraction Analysis 
X-Ray diffraction analysis (Rigaku Geigerflex DMAX III/C) allowed to identify 
the chemical composition of samples using monochromatic CuKα (1.54056 Å) radiation at 
40kV. The 2θ scan range was 3-80o with a scanning speed 3o/min. 
 
Density Studies 
Densities of the scaffolds were calculated by dividing the mass of the scaffold by 
their volume. The mass was measured in an analytical balance with precision of 0.1mg and 
 the size was measured by a micrometer. 
specimens for each type of scaffold
 
Microstructure of Scaffold 
Scaffold morphology was evaluated by scanning electron microscopy (SEM
Hitachi SU-70). Samples were 
glued to the sample holder with the 
with conductive layer of gold
magnifications. 
 
Figure 4-7 Prepared samples for SEM observation: (a) CaP powders; (b) and (c) CH/CH composite 
 
Average pore size of obtained 
from 15-20 of pores.  
Figure 
 
Three-dimensional reconstruction of scaffo
(SKYSCAN 1072) in Characterization Lab II at 3B’s Research Group, Department of 
Chapter 4: Experimental Procedure
33 
Each value of density was an average from 3
.  
immersed in liquid nitrogen, cut into smaller pieces
use of carbon-glue (as illustrated in Figure 
-palladium; and observed in SEM at 15kV using different 
 
scaffold 
scaffolds were calculated using ImageJ (
 
4-8 Pore Size Calculation using ImageJ 
ld structure was done by µ
 
 
-5 
 
, and 
4-7); coated 
Figure 4-8) 
-CT 
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Polymer Engineering, UMinho, Guimaraes, Portugal. The selected samples, CH-fibers/pH 
5/(-15oC), CH-fibers/pH 5/0oC, CH-fibers/pH 5/(-196oC), and CH-fibers/pH 2/(-15oC) 
were chosen to be representative to study the influence of pH and freezing temperature. 
Each sample was cut into small cylinder in the size of ~3mm in diameter and ~7-10mm in 
height. 
 
Compressive Test 
The scaffolds compressive mechanical behavior for the as prepared scaffold 
(without ethanol treatment) was tested using a Bose Smart Test equipment as shown in 
Figure 4-9. The specimens were cylindrical about 17-19mm high and 15-17mm in 
diameter. The crosshead speed was set at 1mm/min, and the load was applied until the 
specimens deformed to approximately 60-70% of its original thickness. At least three 
specimens were tested for each type of samples.  
 
 
Figure 4-9 Compression Test Apparatus 
 
The strain-stress curves were built based on the data obtained from the machine. 
The compressive modulus was calculated as the slope of the initial linear region; while the 
compressive strength was taken from the intersection between the linear line and the 
plateau region.  
 
In vitro biomineralization studies 
In vitro biomineralization in SBF (simulated body fluid) was done to the selected 
samples to observe the bioactivity of the scaffold. The selected samples: pure CH/pH 5/(-
15oC), CH-fibers/pH 2/(-15oC), and CH-fibers/pH 5/(-15oC) were chosen to compare 
different biomineralization ability between pure & composite scaffold and also the 
composite scaffold which were prepared at different pH.  
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SBF with the composition shown in Table 2-3 were prepared following the 
procedure by Kokubo and Takadama24. The reagents which were used to prepare 500mL 
of SBF were listed in Table 4-3. 
To prepare 500 mL of SBF, first of all, 350 mL of deionized water was put in a 
glass beaker and heated to 36,5±1,5oC under stirring. Reagents 1 to 8 were dissolved one 
by one following their order. Reagent 9 (CNH2(CH2OH)3) was added drop by drop while 
monitoring until it reached pH 7,45. At this value the addition of reagent 9 was stopped 
and HCl 1M was added in order to lower the pH to 7,42. Again reagent 9 was added until 
pH raised to 7,45. This process was repeated until all reagent 9 was dissolved.  Finally, 
HCl 1M was added to adjust the pH to 7,40. The solution was poured to volumetric flask 
and subsequently deionized water was added until a final volume of 500mL. SBF was 
stored in fridge (5-10oC) and shall be used within 30 days after preparation.  
 
Table 4-3 Reagents for Preparing SBF 
Order Reagent Quantity Supplier Purity (%) 
1 NaCl 3,998 g Merck 99,5 
2 NaHCO3 0,175 g Riedel-de Han 99,7 
3 KCl 0,112 g Merck 99,5 
4 K2HPO4.3H2O 0,114 g Merck 99 
5 MgCl2.6H2O 0,1525 g Merck 99-102 
6 HCl 1M 19,5 mL Prepared in the lab 
7 CaCl2.6H2O 0,274 g Fluka 99 
8 Na2SO4 0,0359 g Panreac 99 
9 CNH2(CH2OH)3 3,0285  g Riedel-de Han 99,5 
10 HCl 1M 0-5 mL Prepared in the lab 
   
 
Figure 4-10 Samples for bioactivity test in SBF: blank SBF (left), chitosan/chitosan composite scaffold 
(middle and right) 
 
Bioactivity test was carried out by immersing a certain size/mass of scaffold in 
SBF (Figure 4-10). The scaffolds used were ethanol-treated scaffolds. As-prepared 
scaffold from freeze-drying cannot be used since the acetic acid left in the surface trigger 
dissolution of chitosan scaffold. 
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SBF was put in plastic bottles and placed in oven to maintain the temperature at 36-
37oC. The volume of SBF that was used for testing was calculated based on equation 4.3. 

 =  /10 (4.3) 
 
where Vs is the volume of SBF (mL) and Sa is the apparent surface area of specimen 
(mm2)22. For porous materials, the volume of SBF should be greater than the calculated 
one.  
After immersion for different periods of time (7, 14, and 21days), the scaffolds 
were separated from the liquid part, washed with deionized water, frozen with liquid 
nitrogen, and freeze-dried for at least 24 hours. The morphology of the samples after being 
immersed in SBF was investigated by SEM. Energy-dispersive X-Ray (EDX) 
spectroscopy analysis was performed on Hitachi SE-70 SEM equipped with Bruker AXS 
Microanalysis. X-Ray diffraction analysis (Rigaku Geigerflex DMAX III/C) and Fourier 
transform infrared spectroscopy – attenuated total reflectance (FTIR-ATR), using FT-
Infrared Bruker Optics Tensor 27 were performed to allow identification of the chemical 
phase or functional groups.  
The liquid parts were collected with a syringe equipped with 0.22µm filter and 
analyzed by inductively coupled plasma spectroscopy (ICP) to measure the Ca & P 
concentrations.  
The variations of Ca and P concentrations are expressed as ∆Ca and ∆P in mg/L 
which are calculated based on equation 4.4. and 4.5. 
∆ = 	 − 
     (4.4) 
∆ = 	 − 
     (4.5) 
Where 	 and 	 are initial concentrations before sample immersion and 

 and 
 are concentrations after immersion of a certain time. If ∆Ca and ∆P are 
positif, it means that there are decreases of ions concentrations. 
 
4.3.3. Drug-Loaded Composite Scaffold  
 
In vitro dexamethasone release in PBS 
Release studies of DEX were conducted in PBS (phosphate-buffered solution) at 
pH 7.4 and 37oC. PBS was prepared by mixing 405mL of 0.2 M Na2HPO4.2H2O and 
95mL of 0.2 M NaH2PO4.H2O.  
To perform the drug release test, specimens with size around 10x6x4 mm3 and 
mass around 0.012-0.017g were immersed in 10mL PBS in plastic bottles and kept at 
37oC. Figure 4-11 illustrated the drug release test in which a number of containers were 
prepared. After predefined time intervals, the scaffold was separated from the solution. 
The solution aliquots were withdrawn using a syringe equipped 0.22µm filter and placed in 
a plastic container.  
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Figure 4-11 Illustration of drug release test in which one piece of scaffold is immersed in PBS for each 
time of sampling 
 
The evaluation of the DEX concentration in the released medium was carried out 
by UV-Visible spectroscopy (UV-3100 Shimadzu) at a wavelength of 242 nm. A standard 
calibration curve was obtained when DEX standard concentration solutions in PBS 
medium were used.   
 
Microstructure of Scaffolds 
Scaffold morphology after and before PBS immersion was investigated by Hitachi 
SU-70 SEM. Samples were observed by SEM at 15kV using different magnifications. 
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Chapter 5  
Results & Discussions 
 
In the present chapter, the results respecting (i) the precipitation and 
characterization of calcium phosphate  (CaP) particles,  (ii) the preparation and 
characterization of chitosan (CH)-based scaffolds and (iii) the drug (dexamethasone, DEX) 
release behaviour of DEX loaded scaffolds will be analysed and discussed in the following 
sections, i.e. sections 5.1, 5.2, and 5.3, respectively.  
 
5.1. Precipitation of HA Fibers  
The experimental results respecting the crystal phase composition and morphology 
aspects of the precipitated calcium phosphate (CaP) particles obtained by the refluxing 
method will be firstly presented. A comprehensive discussion aiming to compare these 
results with the previous ones reported for the same method by Aizawa et al.56 will be then 
attempted. 
 
5.1.1. Crystal phase composition of precipitated CaP particles  
As mentioned in the experimental procedure, two different methodologies were 
followed aiming at obtaining HA fibers: (1) refluxing the precipitating medium at 80oC for 
24h and then at 90oC for 72h and (2) refluxing the solution for 4h at 80oC and then at 90oC 
for 72h.  
Figure 5-1 and Figure 5-2 show the evolution of the XRD spectra for the CaP 
precipitates withdrawn from the precipitating medium after different periods of time. It is 
observed that incipient monetite peaks start being detected after 30min of refluxing which 
then become more intense and sharper after 60min (Figure 5-1). OCP diffraction peaks 
started to be noticed after 20 hours. Both the peaks of monetite and OCP became sharper 
with the increase of refluxing time. After 24h at 80ºC monetite and OCP are still the main 
crystalline phases being detected. This crystalline phase evolution of the precipitates is 
accompanied by a significant pH variation within the precipitating medium, from ~1 to ~5 
as depicted in Figure 5-3. When the particles obtained after refluxing at 80ºC for 24h are 
now exposed to refluxing at 90ºC during 72h, HA is the dominant crystalline phase with 
some OCP still detected in the XRD. As shown in Figure 5-3, HA crystallization is 
followed by a pH increase to 7.5. 
Figure 5-2 illustrates the diffraction peak evolution for the particles precipitated by 
the second methodology, i.e. the CaP precipitates obtained after 4h at 80ºC and then 
refluxed at 90oC during 72h. After refluxing at 90oC for 24h HA peaks become noticed as 
well as a strong OCP peak. As refluxing at 90ºC goes HA peaks become more intense 
while OCP is unnoticed. After 72h at 90ºC the precipitated particles evidence HA as the 
dominant crystalline phase with traces of monetite. It thus concluded that the increase of 
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the refluxing temperature from 80oC to 90oC has speed up the formation of HA crystalline 
phase.  
 
Figure 5-1 XRD spectra of CaP precipitates showing an increase of peaks’ sharpness of monetite and 
OCP during 24hours-reflux at 80oC 
Table 5-1 shows the crystallite size development of the three main compounds 
detected in XRD (monetite, OCP, and HA) during precipitation. It is observed that both 
monetite and OCP present crystallite size variation curves with maxima while HA 
crystallite size values increase continuously during refluxing at 90ºC. Moreover it is 
evident that regardless the used methodology HA crystallites after refluxing at 90ºC are 
well developed with sizes in the range 170 – 180 Å   
 
Table 5-1 List of crystallites size which increase and decrease during reflux 
Samples Monetite OCP HA 
2h 80oC 61.77 Å - - 
4h 80oC 151.39 Å - - 
8h 80oC 136.81 Å - - 
20h 80oC 126.43 127.51 Å - 
24h 80oC - 226.37 Å 121.25 Å 
24h-80oC + 72h-90oC  133.18 Å 186.43 Å 
4h-80oC + 24h-90oC - 137.44 Å 133.24 Å 
4h-80oC + 48h-90oC - 82.15 Å 143.55 Å 
4h-80oC + 72h-90oC 54.97 Å - 170.08 Å 
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Figure 5-2 XRD spectra showing a decrease of OCP peaks and a increase of HA peaks during reflux at 
90oC 
 
Figure 5-3 pH dependence of the reflux time and temperature during the HA precipitation process 
(24h 80oC + 72h 90oC) 
5.1.2. Crystal Morphology 
Figure 5-5 shows SEM images of CaP precipitates obtained after refluxing at 80 
and 90oC for different periods of time. Different morphologies are revealed as the 
refluxing time increases:  a mixture of spherical particles and thin platelets assembled in a 
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florrete-like structure is evidenced after a short period, i.e. 30min, which then converts to 
thicker platelet-like particles and later on to a prismatic morphology as refluxing 
continues; after longer periods fibers start to be noticed and become the dominant shape 
after 24 hours. It is worthy to be mentioned that no relevant morphology change is noticed 
when the fibers obtained after refluxing at 80ºC are subsequently refluxed at 90ºC. 
Futhermore, it is observed that fibers are also obtained when the prismatic particles formed 
after refluxing at 80ºC are then submitted to a 90ºC refluxing.  
The evolution of the specific surface area of CaP precipitates during precipitation is 
illustrated in Figure 5-4. The surface area decreased drastically from 30m2/g to 0.6m2/g 
during the first 4 hours of refluxing being this low value maintained during the remaining 
refluxing time. The subsequent refluxing at higher temperature (90ºC) allowed a slight 
increase of the specific surface area to 2m2/g.  
 
Figure 5-4 variations of precipitates specific surface area during HA precipitation process (4h 80oC + 
72h 90oC)  
5.1.3. Growth of HA fibers 
 
HA particles precipitation from moderately acidic solution is also known as a soft 
chemical route in which no subsequent high-temperature annealing process is required for 
obtaining the desired crystal phase. HA fibers precipitation is a complex process since it 
might not only involve nucleation and growth of a single crystalline phase but rather 
secondary nucleation or phase transformation13. A number of experimental conditions 
which influence HA precipitation are known to be reagents concentrations, molar ratio of 
precursor ions, pH, temperature, presence of additives among others13, 38, 39. In the present 
work, Ca(NO3)2 and (NH4)2HPO4 were used as source reagents of calcium and phosphate, 
respectively; HNO3 and urea were used as additives for pH control.  
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a. 30min-80oC 
 
b. 2h-80oC 
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c. 4h-80oC 
 
d. 8h-80oC 
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e. 20h-80oC 
 
f. 24h-80oC 
 
 
 
 
 
  
g. 4hours-80oC + 24hours
 
i. 4hours-80oC + 72hours
Figure 5-5 SEM Images of CaP precipitates with different time 
precipitates in different magnifications. Figure b show the heterogeneity of samples formed after 2hours
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-90oC 
 
h. 4hours-80o
-90oC  
 
j. 24hours-80
and temperature of reflux. Figure a, c, d, e and f on the left side and on the right side show CaP 
-80oC reflux.  While Figure g, h, i and j show CaP fibers for 
further reflux with almost similar morphology
 
 
C + 48hours-90oC 
 
oC + 72hours-90oC 
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Figure 5-6 phase composition estimation and crystal morphology evolution during refluxing using two different pathways (a) 4h-80oC+72h-90oC and (b) 24h-
80oC+72h-90oC 
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Figure 5-6 puts together the properties variation of the precipitates during the 
refluxing process, i.e. their crystal phase composition particle morphology. For 
comparative purposes, the relative amount of each phase estimated trough XRD peak area 
calculations is also presented. The overall results show basically that CaP precipitation can 
be divided into three main stages: (1) formation of platelets shaped monetite, (2) formation 
of fibers-like OCP, and (3) transformation of fibers-like OCP crystal into HA.  
In the first stage, as shown in XRD spectra on Figure 5-1, incipient monetite 
appeared after 30min refluxing. This is in line with the findings from H. Zhang et al.39 
which demonstrated that during this process, urea decomposes and contributes to pH 
increase until a critical (2,4-3,1) pH range where monetite starts precipitating, the sooner 
the higher is the temperature: after 12 min at 95oC, 28 min at 90oC, and 46 min at 85oC. In 
the present case crystalline monetite was obtained at 80ºC after 1 hour at pH~ 2. Other 
references which also studied HA precipitations are Aizawa et al.38, 56. However, none of 
them followed the crystal morphology evolution during the precipitation process.  
 Monetite is the first CaP phase to be precipitated. According to CaP solubility 
isotherms (Figure 2-10), at pH<4.5 monetite is the most insoluble CaP phase and thus is 
the first to be precipitated41. After 60min the XRD peaks became sharper indicating a 
higher crystallinity which is reflected by the increase of monetite crystallite size (Table 
5-1). The existence of crystalline monetite is revealed by SEM images as thick platelet 
shaped particles which are very clearly detected after 2hours of refluxing. The specific 
surface area is seen to decrease drastically during the first two hours of refluxing being 
then followed by a slower decrease until 4hours (Figure 5-3). This surface area decreasing 
reflects the growth of the large platelet shaped particles from the small sized spherical 
particles and thin platelets detected at the early stage of the refluxing (Figure 5-5). 
Figure 5-5 (b) also documents the heterogeneity of the precipitates.  Sphere-like 
monetite on Figure 5-5 (b-left) and thick platelet-like shaped monetite Figure 5-5 (b-right) 
coexists in solution after 2h of refluxing. This inhomogeneous condition might indicate 
that some overlap between nucleation and growth probably took place. Further, this fact 
may also explain why the final HA fibers possess a relatively wide range of size (50-
300µm).  
The second stage of the precipitation process involves the formation of OCP. The 
existence of OCP starts to be detected in the XRD spectra (Figure 5-1) after 4h-80oC 
refluxing. The strong peaks of OCP observed in XRD spectra after 20h-80oC refluxing 
corresponds in SEM images to fibers-like OCP (Figure 5-5 (e-f)). At this stage, the 
monetite thick platelets and prisms previously referred transformed into fibers, being 
evident that the grow of particles with fiber-like morphology was already initiated after 4h-
80ºC refluxing (Figure 5-5 (c)). According to solubility isotherms of calcium phosphate 
phases in the ternary system Ca(OH)2-H3PO4-KNO3-H2O at 37ºC (Figure 2-13), HA has 
lower solubility than OCP  in the 3 <pH<10 range. Consequently HA should be preferably 
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formed instead of OCP at a precipitation temperature of 37ºC. As the current experiments 
are being performed at a higher temperature it is anticipated that the temperature 
dependence of OCP solubility might account for some solubility variations as compared to 
HA. Moreover it is also known that kinetic factors may have a considerable effect in 
determining the nature of the CaP phases that precipitate, further helped by anions and 
cations from solution which stabilizing role can not be ruled out41. These arguments may 
explain why OCP preferentially precipitates in a pH range where the solubities of OCP and 
HA are supposed to be very close.  
During the third stage of the precipitation the crystal phase transformation from 
OCP into HA fibers-like particles takes place. As can be seen in the phase composition 
summary presented in Figure 5-6, that phase transformation started to occur after 20h-80oC 
refluxing. OCP transformation into HA is described by the following equation 5-139: 
5Ca8H2(PO4)6.5H2O  → 4Ca10(PO4)6(OH)2 + 6H3PO4+ 17H2O          (5.1) 
    
            (OCP)             (HA)  
For (4h-80ºC+72h-90ºC), the transformation of OCP into HA was completed 
during refluxing at 90ºC though not all monetite had been converted into OCP being thus 
noticed in XRD spectra (Figure 5-1). Once again arguments based on the stabilizer role of 
the precipitation medium ions may be put forward to explain the slow conversion of 
monetite into other thermodynamically more stable CaP phases. For (24h-80ºC+72h-
90ºC), the transformation of OCP seems to be not completed yet, since a small peak of 
OCP still exist. The morphology variations during the last refluxing step at 90ºC were 
meaningless. It is thus concluded that OCP is a precursor phase of HA, behaving like a 
template for HA crystallization as HA fibers keep the shape of OCP fibers.  
Figure 5-5 shows SEM images of the fibers obtained after 4h-80ºC refluxing and 
then refluxed at 90ºC during different times. In spite of the differences underlying the two 
routes, i.e. (24h-80ºC+72h-90ºC) and (4h-80ºC+72h-90ºC), the characteristics of the final 
particles either in terms of morphology or of crystal phase composition are very alike: in 
both cases HA fibers with similar size and crystallite size are the main product of the 
refluxing at 90ºC regardless the duration of the 80ºC refluxing (Figure 5-5). It is thus 
concluded that the incipient OCP, with fiber-like morphology, early detected at 80ºC after 
a 4h refluxing was easily converted into HA fibers at 90ºC, even after 24h. Therefore, 
overall shorter precipitation times are required if refluxing temperature/time relation is 
conveniently manipulated. The present results demonstrate that 76hours, i.e. 
(4h/80ºC+72h/90ºC = 76h) are required for obtaining HA fibers which would otherwise 
require longer times (96hours), i.e.  (24h/80ºC+72h/90ºC= 96h) to precipitate. 
 Temperature may be also manipulated towards lower values for obtaining HA 
fibers. The work from Zhang39 has shown that precipitation of HA at temperatures lower 
than 90ºC is possible but after much longer times: 120 hours under 85ºC refluxing. 
 Despite of its advantage
precipitation method has one main drawback. Since several phase transitions are involved 
in this process, their coexistence in the final product is very likely to occur. For example, 
as shown in the XRD spectra of the 
of monetite. This is also illustrated in 
final precipitate where some non
which didn’t transform completely into HA fibers are still observed. Besides 
thermodynamic and kinetic issues contributing
mentioning that experimental conditions may also account for this fact as precipitation was 
carried out without any stirring. It is foreseen that improving experimental technique in 
future work in order to include 
other CaP phases. 
 
Figure 5-7 SEM images of final precipitates
transition phase (right) which 
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s of being easy to carry out, preparing HA fibers 
Figure 5-2, the final HA fibers contain a small amount 
Figure 5-7 that reveals the non-uniformity of the 
-fiber particle corresponding to a monetite transient phase 
 to this non-homogeneity, it is worthy 
uniform stirring may help to obtain pure HA fibers without 
 after 4h-80oC + 72h-90oC - HA fibers(left); 
might be monetite as shown in XRD spectra
 
 
by this 
 
other 
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5.2. Chitosan based Scaffolds 
 
To fulfill the requirements of a scaffold for bone regeneration, a number of 
parameters should be met as stated in Table 2-1. In the present research, four main 
properties are addressed: (1) the chemical and crystal phase composition; (2) the 
microstructure, including porosity, pore size, and interconnectivity; (3) the mechanical 
properties, evaluated by compressive tests, and (4) the bioactivity. Different chitosan-
based scaffolds, unloaded and loaded with different type of CaP particles, prepared under 
different experimental conditions of chitosan solution pH and freezing temperature will be 
analyzed and comparatively discussed in the present chapter. Table 5-2 presents the 
scaffolds under study and their respective preparation conditions. 
 
Table 5-2 Chitosan and Chitosan composite scaffolds obtained by freeze drying under different 
conditions of : chitosan solution pH, freezing temperature and type of CaP particles loading.   
 pH 2 pH 2 loaded pH 5 pH 5 loaded 
 HA 
Fibers 
 HA 
Fibers 
Monetite 
Powder 
Mixture 
(HA fibers + 
monetite powder) 
Liq N2 √  √ √   
(-15oC) √ √ √ √  √ 
~0C √  √ √ √  
Note: the symbol √ identifies the conditions combination effectively used for   scaffolds preparation. 
 
5.2.1. Influence of pH and Freezing Temperature on CH Scaffold Properties 
 
CH scaffolds were prepared from chitosan solutions with different pH, i.e. pH=2 
and pH=5, and subsequently frozen at different temperatures, i.e. liquid nitrogen (-196ºC), 
-15ºC and 0ºC. All the samples collected from freeze drier looked like white spongy bodies 
but exhibiting different shrinkage. As illustrated in figure Figure 5-8, chitosan scaffolds 
prepared at pH 5 showed larger shrinkage as compared to pH=2 and consequently higher 
geometrical density (Table 5-3). 
 
Figure 5-8 Top views (left image) and front views (right image) of chitosan scaffolds prepared under 
different pH conditions and frozen at (-15oC) 
Chapter 5: Results & Discussions 
 
 
51 
 
Table 5-3 List of CH composite scaffolds and and respective density values prepared with different pH 
and freezing temperature 
 
pH 2 pH 2 loaded pH 5 pH 5 loaded 
 
HA 
Fibers  
HA 
Fibers 
Monetite 
Powder 
Mixture 
(HA fibers + 
monetite 
powder) 
-196oC - - 0.0524 0.0714 - - 
-15oC 0.03686 0.05074 0.0541 0.0628 - 0.0689 
0C - - - - 0.06167 - 
 
These macroscopic differences were followed by microstructure variations, too. 
The microstructures of the obtained chitosan scaffolds are imaged in Figure 5-10. 
Interconnected porous structures are generally observed but with differently sized pores, 
thus denoting a significant effect of pH and freezing temperature on the scaffold 
microstructure.   
For the freezing temperatures of 0oC or (-15oC), pH effects on pore size reveal a 
slight tendency for larger pores to be obtained at higher pH (pH=5), as shown in Figure 
5-10 (a b, d and e). The calculated average pore sizes presented in Figure 5-9 confirm that 
scaffolds prepared from chitosan solution at pH 2 resulted in slightly smaller pore size.  
The study of freezing temperature influence in chitosan and alginate has been done 
previously by Madihally and Matthew18 and ZMora et al.58. The results shows similar 
trend regarding to freezing temperature. However, an attempt to study the effect of pH, 
haven’t been done so far.  
 
Figure 5-9 Effects of freezing temperature and pH of chitosan solution on mean pore size diameter of 
chitosan scaffolds 
Regarding the freezing temperature effects, a clear tendency for smaller pores as 
the freezing temperature decreases is observed on the scaffolds prepared at pH 2.  
  
Figure 5-10 SEM images of pure CH scaffold at pH 5 (top images) and pH 2 (bottom images) with freezing temperature: ~0
52 
 
196oC (right) 
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However, scaffolds prepared at pH 5 do not follow that trend and a quite different pore 
structure was obtained for the freezing temperature of -196oC (liquid N2): the pores are 
larger and seem to be apparently less interconnected than in the other scaffolds. 
Furthermore freezing scaffold at -196oC also resulted in thicker wall pore as can be seen in 
Figure 5-11. 
 
 
Figure 5-11 Higher magnification of SEM images show wall thickness of: pure CH/pH5/(-196oC) (left) 
and pure CH/pH5/(-15oC) (right) 
 
It is known that the morphology of the scaffolds manufactured by thermal induced 
phase separation process depends on several experimental variables such as freezing 
temperature, freezing rate, solution concentration, solvent type and polymer molecular 
weight among others18. When a chitosan solution is frozen, the magnitude of the 
temperature gradient (∆T) imposed during freezing quantifies the equilibrium deviation of 
the solution so that the higher ∆T the higher is the driving force for ice nucleation and 
growth. This reasoning anticipates that lowering freezing temperature enhances nucleation 
rate and thus favors smaller sized pores to be formed. The results obtained at pH=2 (Figure 
5-10 a, b and c) seem to fit well to this idea since they point out a trend of pore size 
decrease with freezing temperature decrease. However increasing the chitosan solution pH 
from 2 to 5 originates a deviation from that trend. As observed from Figure 5-10 (d and e) 
pore freezing at 0 or -15ºC resulted in pore sizes slightly larger than their counterparts at 
pH=2, though less affected by freezing temperature variation. Furthermore, when freezing 
at -196 the largest pores were obtained. As these results reflect the joint effects of 
temperature and pH variation it seems that chitosan solution pH plays an important role in 
the scaffold microstructure design. 
 It is known that pH variations modulate the amount of cationic groups bounded to 
chitosan molecule as described by equation 5-2:   
  
Chit-NH2 + H3O+ → Chit-NH3+ + H2O 
 
(5.2) 
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Chitosan bounded –NH3+ groups impart to chitosan a polycationic condition that 
helps maintaining the chains free of attractive interactions among them. This cationic 
condition explains the pH dependence of chitosan solubity59. At higher pH (pH=5), 
bearing a smaller cationic [NH3+] load, chitosan chains may agglomerate easier in solution 
and form polymeric structures. This will also contribute to increase the viscosity of 
chitosan solution60 as was experimetally observed indeed: after adding NH4OH to chitosan 
solution to increase its pH from 2 to 5, the resulting solution showed to be effectively more 
viscous. Thus, for interpreting the pH effect on pore size Figure 5-10 (a, b, d and e) it is 
thus suggested that the more protonated chitosan chains (pH=2) ensure a true chitosan 
solution condition in which homogeneous nucleation of ice crystal occurs whereas the less 
protonated chains condition (pH=5) are prone to the formation of polymeric structures 
which might offer preferential sites for ice crystal nucleation. In this condition (higher pH) 
and under a very fast freezing imposed to the solution (-196ºC) it is here suggested that 
cationic sites probably play as favorable sites for ice nuclei formation and thus, as 
compared to the first condition (lower pH), a lower amount of ice nuclei is formed and 
thus allowed to grow further. 
The large pores obtained after freezing in liquid N2 indicate that freezing under 
liquid nitrogen temperature did favor ice crystal growth rather than ice crystal nucleation. 
It is thus postulated that the scarcity of cationic groups limits the benefit of large ∆T in 
nucleation rate which starts occurring at preferential cationic sites; once nucleated, the ice 
nuclei find appropriate conditions (large ∆T) to undergo a higher growing rate as 
compared to the other freezing conditions. 
5.2.2. Chitosan/CaP Composite Scaffolds 
 
In the present section the effects of the processing conditions (pH and freezing 
temperature) and of the used CaP particles as reinforcement elements on CH/CaP 
composite scaffolds characteristic are analyzed and discussed. Two different reinforcement 
particles were used in this current research: HA fibers (4h-80oC+72h-90oC reflux), 
florrete-like monetite powder (30min-80oC reflux) and a mixture between these two 
particle type  was also used in order to understand their differences. 
 
5.2.2.1. Scaffold Microstructure 
Chitosan scaffolds loaded with different types of CaP particles were produced from 
CaP particles suspensions in chitosan solutions upon freezing at -196ºC, -15ºC or 0ºC. As 
noticed before the variation of CH solution pH produced a significant effect on the freeze 
dried CH-HA scaffold either at a macroscopic level either from the microstructure point of 
view. Following the same tendency exhibited by CH scaffolds (discussed in the previous 
section) the preparation from pH 5 solutions originated larger shrinkage. The calculated 
geometrical densities values presented in Table 5-3 reflect this pH shrinkage tendency. 
 Figure 5-12 illustrates the microstructure of the freeze
loaded with different types of CaP particles (CH
particles for scaffolds loading are also presented in the same figure: (i) HA 
by the method (4h-80ºC+72h-
Figure 5-12 SEM images of reinforcement particles
and its produced scaffolds: CH-fibers at 
~0oC/pH 5(g) and mixture of incipient monetite and HA fibers at 
In general, the scaffolds microstructures evidence porous bodies with differently 
sized open pores uniformly distributed with an apparent high degree of interconnectivity. 
Higher magnification views of the pore walls also allows us to detect the presence of the 
fibers embedded in the polymeric wall
prepared at pH 5 where fibers are clearly revealed (
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-dried chitosan scaffolds 
-HA scaffolds). Pictures of the used CaP 
fibers produced 
90ºC), and  (ii) incipient monetite (30min-80oC reflux)
: (a) HA fibers and (f) incipient monetite powder 
-15oC/pH 5 (b, d) and -15oC/pH 2 (c, e); incipient monetite at 
-15oC/pH 5 (h)
s (Figure 5-12 d and e): in the case of the scaffolds 
Figure 5-12 d) whereas for pH 2 fibers 
 
 
.  
 
 
 are less abundant and shorter 
in the previous section, the CH
size as compared to those prepared at pH 5.
Concerning freezing temperature effects (
the samples prepared at -196
obtained at -15oC (Figure 5-13
 
Figure 5-13 SEM images showing different pore sizes of CH/Fibers scaffold prepared at pH 5 with 
different temperature: (a) 
The 3D reconstruction obtained by µ
scaffolds. The resulting porosity, pore size, and interconnectivity data are presented in 
Table 5-4. Total porosity and interconnectivity are seen to decrease as the free
temperature decreases too. Using lower pH is also seen to decrease the pore size. 
 
Table 
Sample 
CH-HA fiber/pH5/LiqN2 
CH-HA fiber/pH5/-15oC 
CH-HA fiber/pH2/-15oC 
a
volume of pores divided by sum of volume of pores
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(Figure 5-12 e).  In line with CH scaffolds behavior
-HA fibers scaffolds produced at pH 2 show smaller pore 
  
Figure 5-13 a,b and d), the p
oC (liq N2) (Figure 5-13) appear to be larger
 b) or 0oC (Figure 5-13 c).  
-196oC, (b) -15oC, and (c) 0oC 
-CT is shown in Figure 5-14
5-4  Data obtained from µ-CT analysis 
Porositya (%) Pore size (µm) Interconnectivity
80,6 190 91,6
90,7 152 98,5
90,7 136 98,0
 and scaffold x100% 
 
 
 reported 
ore sizes of 
 than those 
 
 for selected 
zing 
 
b
 (%) 
 
 
 
 bvolume of interconnected pores divided by sum of interconnected pores and closed pore x 100% (in this calculation, 
pores smaller than 5µm are neglected) 
Figure 5-14 3D reconstruction made by 
CH-fiber/pH2/-15oC; where 1 refers to total reconstruction and 2 refers to reconstruction of the 
 
Figure 5-14 also shows that for the scaffolds prepared at 
reconstruction both in total and mineral reconstructions presents a more homogeneous 
structure than for scaffolds prepared at 
lower than in the previous ones.
Chitosan scaffolds prepared with addition of CaP 
materials in which a continuous polymeric matrix hosts a discontinuous CaP phase aimed 
at reinforcing the scaffold structure. Composite properties are strongly influenced by the 
properties of the constituent materials, their distribution, and the interaction between 
them61, 62. Besides the properties of constituent materials, it is also 
geometry of the reinforcement (including shape, size and distribution size). The geometry 
of the reinforcement plays an important role in the strengthening mechanism.
The values of solution pH and freezing temperature influence the
composite scaffolds in a way similar to that
showed that smaller pore are obtained at pH 2 as compared to pH 5. He
discussed for CH solutions seems t
influence of temperature at pH 5 (
smaller pore size than 0oC and Liq N
particles in CH solution did not alter significantly the 
rates as compared to pure chitosan solution. Fur
scaffolds was also consistent with that observed with CH
also larger for scaffold prepared at pH 5. Accordingly the density values of the CaP loaded 
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µ-CT, A: CH-fiber/pH 5/LiqN2; B: CH-fiber/pH5/
mineral part only 
-15ºC pH 2, the 3D 
-196ºC; in this last case the interconnectivity is also 
 
particles viewed as 
necessary to address the 
 
 pore sizes of CH 
 observed for pure CH scaffold. 
nce the pH role 
o be maintained in CaP loaded CH solutions. The 
Figure 5-13) revealed that freezing at (-15oC) resulted
2. It is thus suggested that the incorporation of CaP 
ice crystal nucleation and growth 
thermore the shrinkage behavio
 scaffolds:  the size reduction was 
 
 
 
-15oC; C: 
composite 
pH variation 
 in 
r of the 
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scaffolds showed to increase with pH, being obviously higher than those of their CH 
scaffolds counterparts (in Table 5-3). 
SEM images have revealed the samples pores size while porosity and 
interconnectivity could be accessed by µ-CT. CH composite scaffolds prepared by 
quenching in liquid N2 showed to display the lowest interconnectivity and porosity which 
confirmed the indication of SEM images (Figure 5-13) that this scaffold seems to be less 
interconnected than the remaining ones. Composite scaffolds prepared at -15oC under two 
different pH values showed similar porosity values, nearly similar interconnectivity and the 
same tendency of pore size variation evidenced by SEM pictures.  
The obtained values of porosity and interconnectivity for the scaffolds CH-
fiber/pH5/-15oC and CH-fiber/pH2/-15oC are quite satisfactory. The porosity value which 
is 90.7% is within in the range of the porosity typically required for promoting proper new 
bone growth (90%)21. The interconnectivity degrees, i.e. 98.5 and 98 respectively, are 
extremely valuable for perfusion and cell migration63. 
Quenching composite solution in liquid nitrogen resulted in lower porosity and 
interconnectivity degree. The value of porosity which is 80.6% is relatively low for bone 
regeneration. Regarding to interconnectivity degree, a clear reference to a minimum value 
could not be found in the literature, so far. For comparison, Darling and Sun63 obtained 
PCL scaffold with interconnectivity degree in the range of 98.16-99.59% and Ho and 
Hutmacher64  gained 100% interconnectivity by preparing scaffolds from copolymer of 
PEG, PCL and PLA with rapid prototyping. As compared to these data, 91.6% of 
interconnectivity seems to be apparently low.  
5.2.2.2. Phase Composition 
Figure 5-15 shows the XRD spectra of CH-HA fibers composite scaffolds prepared 
at different pH, i.e. pH=2 and pH=5. It is observed that the scaffold obtained from pH 5 
chitosan solution reflects the peaks of HA superimposed on a baseline showing the 
chitosan hump at 2θ=20º. However for the scaffold prepared at pH=2, both  HA peaks and 
brushite peaks are detected. 
The presence of brushite in the CH-Fibers prepared at pH 2 indicates that part of 
HA transformed to brushite during the scaffold preparation. Such phase transformation 
probably occurred via partial dissolution of HA fibers in the acidic conditions (pH=2) of 
chitosan solution followed by brushite. This partial dissolution/recrystalization of HA 
fibers may also explain why less and smaller fibers are detected on the pore walls of the 
scaffolds prepared at pH 2 as compared to pH 5 (Figure 5-12 d and e)). A phase 
transformation was also observed on CH-incipient monetite scaffolds prepared at 
pH=5.Monetite was seen to transform into HA as shown in Figure 5-15 E. CaP dissolution 
and recrystallization as a crystalline phase different from the initial one has been seldom 
reported, depending on the pH conditions72, 65.  
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Figure 5-15 XRD Spectra of (A) pure CH, (B) HA fibers, and (C) CH-HA fibers/pH 5, (D) CH-HA fibers/pH 5, (E) CH-Incipient monetite/pH 5, all frozen at 
(-15oC), and (F) CH-mixture CaP/pH 5 frozen at 0oC  
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5.2.2.3. Mechanical Properties 
In the case of composite scaffolds to be used as support for bone regeneration, the 
improvement of mechanical properties while ensuring an adequate microstructure with 
sufficient large pores for vascularization and tissue ingrowth is a critical issue. It is known 
that the type of reinforcement together with the processing variables may influence the 
pore structure and porosity and hence the mechanical response of the scaffold. Concerning 
the particles used as reinforcement, depending on their geometry, they may also affect 
differently the porosity66 and pore orientation67 and thus the mechanical properties. To 
exploit the simultaneous effects of these experimental variables, different processing 
conditions (pH and freezing temperature) and different CaP loading were selected for the 
present study. 
Figure 5-16 shows the stress-strain curves of various scaffolds, including CH and 
CaP loaded CH scaffolds. The stress-strain curves evidence two main regions: (1) initial 
linear loading regime denoting an elastic behavior and (2) a plateau region which refers to 
the collapse or cell wall buckle10. Two main properties may be calculated from these 
curves: the compressive modulus – from the initial linear behavior and the compressive-
strength – as the highest point which is taken from the intersection between linear behavior 
and plateau region. It is generally shown that (1) loading the chitosan matrix with calcium 
phosphate particles resulted in higher mechanical property; (2) the type of reinforcement 
also affected the scaffolds mechanical properties and (3) the CH-fibers composite scaffolds 
prepared at pH 2 (-15ºC) exhibited the highest compressive modulus and strength. 
 
Figure 5-16 Mechanical Properties of CH and CH composite scaffold 
 Table 5-5 List of Scaffold Mechanical Properties (M: modulus; S: strength
 pH 2 pH 2 loaded
 HA 
Fibers 
-196oC - - 
-15oC M=0.2 
S=0.02 
M= 2.58±0.34
S= 0.158±0.022
0C - - 
 
Table 5-5 summarizes the
the strength of the various CH and CH composite scaffolds prepared at different 
conditions. The rule of mixture
by loading CH scaffold with CaP particles: CaP phase is a ceramic more brittle and 
stronger than chitosan polymer
 
Figure 5-17 SEM image of CH-
properties among the prepared scaffolds
Regarding the pH effect, scaffolds prepared
properties than scaffolds prepared at pH
(M: ~2,58 MPa; S: ~0,18 M
Zhang10. It is worthy mentioning that in spite of having smaller pore size as compared to 
the scaffolds prepared at pH5, their microstructure seems to be rather uniform with well 
interconnected pores as illustrated in 
mechanical properties as reported by Yu et al.
and porosity of PCL on scaffold mechanical properties. The
mechanical properties are influenced by pore size, porosity and interconnectivity. Smaller 
pore size, lower porosity, and lower interconnectivity lead to higher modulus. Among the 
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; both in MPa
 pH 5 pH 5 loaded 
 HA 
Fibers 
Monetite 
Powder (HA fibers +
- M= 0.616±0.10 
S= 0.112±0.028 
- 
 
 
M=0.65 
S=0.025 
M=0.79±0.4 
S=0.048±0.007 
- M=0.64
S=0.079
 - M=1.1±0.35 
S=0.09±0.01 
 mechanical properties, i.e. the compressive modulus and 
68
 may explain the improvement of mechanical properties 
21
.  
 
HA fibers prepared at pH 2 (-15oC) which has the best mechanical 
 
 at pH 2 showed better
 5. Their modulus and compressive strength values 
Pa) are comparable to the values reported by 
Figure 5-17. These conditions enhance the 
69
 who investigated the influence of por
ir results showed that 
 
 
) 
Mixture 
 
monetite 
powder) 
- 
±0.16 
±0.007 
- 
 mechanical 
Zhang and 
e size 
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prepared scaffolds and in terms of biomedical applications, the scaffold illustrated in 
Figure 5-17 seems to be one offering a good combination of mechanical properties and 
microstructure for tissue regeneration purposes. 
Furthermore, it was also shown that a partial dissolution and recrystallization of 
calcium phosphate fibers did occur. It is also thought that this fact may have favored a 
stronger bonding between the recrystallized particles and the polymer matrix thus 
contributing for mechanical properties enhancement too. It has been reported that the 
interaction between the reinforcement particles and the matrix is crucial for load transfer 
between the two phases as a lack of adhesion between them results in early failure/low 
mechanical properties16. Reinforcing chitosan polymer with HA particles under two 
different pH conditions may affect differently the chemical bonding between the matrix 
and the CaP particles as chitosan cationic groups may effectively condition the bonding 
strength between the two phases. 
The results of Figure 5-16 also evidence that the freezing temperature during TIPS 
also affected the scaffolds mechanical properties. Comparing the HA fiber loaded 
scaffolds (pH5) frozen at different temperatures, i.e. -15ºC and 196ºC, an improvement of 
compression strength accompanied by a decrease of  compression modulus is observed for 
the scaffold quenched in liquid nitrogen temperature. The reasons underlying this behavior 
are not completely clear. Probably, taking into account the results from SEM and µ-CT 
analysis (Figure 5-13 and Figure 5-12), it can be considered that close pores and thicker 
wall of pores (Figure 5-11) might be important reasons accounting for this phenomenon, in 
line with the findings of Yu et al.70  .  
Two types of reinforcements were used aiming to improve mechanical properties. 
A pH 5 CH solution was used in order to avoid CaP dissolution. Different values of 
mechanical properties were measured for scaffolds loaded with HA fibre, incipient 
monetite and mixture of HA fibers and incipient monetite (HA: monetite = 3 : 2).The 
results show  that the incipient monetite powder and its mixture with HA fibers loading 
enabled higher compressive strength compared to CH-fibers. As pointed out before, 
properties of a composite depend on several variables such as reinforcement size, size 
distribution and shape. It has been reported that irregular shape is preferred to spherical 
shape since it can form better interfacial bonding with the polymer62. Figure 5-12 (a and f) 
shows the two type of reinforcements which were used: HA fibers and incipient monetite 
powder. It is here suggested that the better mechanical properties achieved with the 
mixture of HA fibers and incipient monetite powder compared to the reinforcement 
provided by HA fibers alone may be due to the irregular and non-smooth surfaces of 
incipient monetite powders which may favor a better connection between these particles 
and the polymer itself. The fibers flat surfaces are thought to ensure a lower mechanical 
interlock with the polymer as compared with monetite particles. 
 5.2.3. Bioactivity Test 
In the beginning of the SBF soaking process the samples underwent a fast swelling. 
Hydrated scaffolds thus present a larger volume as compared to non
5-18 shows how CH composite scaffold swelled due to hydration process during SBF 
immersion during the in vitro 
 
Figure 5-18 CH Composite scaffold: (a) fully hydrated and (b) as prepared
Figure 5-21, 5-22, and 5
during bioactivity tests. It is shown that the pore structure didn’t change significantly for 
the majority of the samples du
(Figure 5-21 d) which exhibited enhanced degradation behavior.
Higher magnification of a por
precipitates which were observed in all the scaffolds. The existence of NaCl was also 
detected in XRD (Figure 5-22
wash procedures, some NaCl crystals still persisted. 
 
Figure 5-19 NaCl fomation on the wall of pure CH 
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-hydrated ones. 
biomineralization test.  
/after ethanol treatment
-23 show the pore structure evolution of the scaffolds 
ring SBF immersion except for CH-fibers/pH 5 after 21 days 
 
e wall surface region allows observing the NaCl 
) and EDS analysis (Figure 5-20). In spite of the repeated 
 
after 7 days (A) and CH-fibers/pH after 14 days 
of SBF immersion 
 
 
Figure 
 
 
 
(B) 
 Figure 5-20 SEM images of scaffold 
fibers/pH 2 showing rough wall in which the EDX spect
 
Besides NaCl precipitation, other type of surface morphology modifications 
occurred for the composite scaffolds during SBF immersion, but not detected in pure CH 
scaffold (as shown in Figure 5
(Figure 5-20 b). EDX analysis on CH
detected that CaP phase with a Ca/P of 1.65 is present. This value reflects the surface and 
underneath adjacent region compositions is close to that of
However EDX analysis of pure CH scaffolds after 21 days immersion did not evidence 
any presence of Ca or P.  
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after 21days of SBF immersion (a) pure chitosan; (b) CH
rum showing Ca and P peaks (Ca/P = 1.65)
-20 a). Rougher walls are shown for the composite scaffolds 
-Fibers/pH 2 scaffolds after 21 days of immersion 
 stoichiometric HA (1.64). 
 
 
 
-
 
 Figure 5-21 SEM images showing porous s
of SBF immersion. Structure damage can be seen clearly in Figure d. 
FTIR-ATR and XRD spectra of the scaffolds after 21days of SBF immersion are 
shown in Figure 5-22 and Figure 
composite scaffolds. However, HA peaks were found to be better defined in CH
2 as compared to CH-fibers/pH 5. In the pure CH scaff
observed. 
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tructures of different type of scaffolds after 14 and 21 days 
  
 
5-23. XRD spectra indicated the existence of HA on both 
old, only NaCl peaks were 
 
 
 
-fibers/pH 
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Figure 5-22 XRD pattern of scaffolds (A) CH-fibers/pH 2, (B) CH-fibers/pH5, and (C) pure CH frozen 
at (-15oC) after immersion in SBF for 21 days, showing HA peaks (*) on composite scaffold; and NaCl 
peaks (#) on pure CH scaffold. 
 
Figure 5-23 and Table 5-6 shows the FTIR spectra and the list of the most 
important absorption bands. The spectra evidence stronger peaks at 635 cm-1 and at 1024-
1095 attributed to the bending vibration of O-H in HA and to stretching vibration bands of 
phosphate group71, respectively, on composite scaffolds as compared to pure CH. These 
bands are particularly intense in the scaffolds prepared at pH 2.  
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Figure 5-23 FTIR spectra scaffolds (A) CH-fibers/pH 2, (B) CH-fibers/pH5, and (C) pure CH frozen at 
(-15oC) after immersion in SBF for 21 days.  
 
Table 5-6 Assignment of FTIR spectra42 presented in Figure 5-23 
IR absorption bands 
(cm-1) 
Description 
~3450 Stretching vibration (N-H) Chitosan 
~1650 Stretching vibration (-C=O-) Amide I Chitosan 
~1590 Amine Chitosan 
~1420 Bending vibration (C-H) Chitosan 
~1153, 1070, 1031 Strecthing (C-O-C) Chitosan 
~1024-1095 Stretching vibration (P-O) PO43- (HA) 
~956 Stretching vibration (P-O) PO43- (HA) 
~635 Bending vibration (O-H)  (HA) 
 
The Ca and P concentration variations in the immersion media (SBF) during the 
soaking period are expressed in Figure 5-24 as depletion amounts. It is observed that for 
CH-fibers composite scaffolds, the SBF solutions depletions increase with the immersion 
time whereas they are not significant in the case of pure CH scaffolds. In the case of the 
composite scaffolds, the CH-fibers/pH 2 scaffold showed to promote a larger depletion of 
SBF P ions as compared to CH-fibers/pH 5.  
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Figure 5-24 Variations on Ca and P concentrations decrease (C0-Ct) of the immersion media after 0, 7, 
14, and 21 days 
 
The decrease of SBF Ca and P concentrations indicate that these ions were 
withdrawn from SBF solutions in the case of the composite scaffolds and precipitate on the 
scaffold pore walls as a CaP phase. For pure CH scaffolds the concentration of both Ca 
and P are relatively stable with negligible variations. Comparing the values of both ∆Ca 
and ∆P of composite scaffolds (CH-fibers/pH 2 and CH-fibers/pH 5) and pure CH, the 
bioactivities of the scaffolds under analysis may be ordered as CH-fibers/pH 2> CH-
fibers/pH 5> pure CH. This result is in line with XRD and FTIR spectra, in which HA 
peaks and phosphate stretching bands are sharper in CH-fibers/pH 2, followed by  CH-
fibers/pH 5, and then by pure CH.  
Bioactivity qualifies the tendency of a material to form a chemical bond with the 
host bone16 and is experimentally denounced by the formation of an apatite layer. The 
precipitation of such CaP layer requires nucleation sites for apatite nuclei to be formed and 
later start growing. CH composite scaffold/pH 2 present a smaller sized porous structure as 
compared to the one prepared at pH 5. Moreover it was shown that the crystalinity and 
crystal phase compositions of the CaP reinforcement (Figure 5-22) is different from that of 
the composite scaffold/pH5.  
The studies on apatite nucleation in biomaterials have revealed that there are a 
number of different mechanisms depending on the materials22. For bioglass and glass 
ceramics which are based on the Na2O–SiO2 or CaO–SiO2 binary system, the SiOH 
functional group favors the apatite nucleation. In the case of HA, Kokubo et al.22 studied 
the mechanism of apatite formation by monitoring the zeta potential prior to immersion in 
SBF. It was shown that in the early time, HA became negatively charged due to its OH- 
and PO43- groups. Because of this negative charge, Ca2+ from SBF were combined with 
HA thus formed Ca-rich calcium phosphate which accumulated and allowed a final 
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positive charge. Further process was combination of PO43- to the existing Ca-rich calcium 
phosphate to lower the Ca/P ratio until reaching the stoichiometric ratio of HA. 
The above mechanism may explain a different stabilization tendency of Ca 
concentration as compared to P concentration. This tendency is clearly shown in CH-
fibers/pH 2 scaffolds (Figure 5-24) as the Ca depletion curve started to stabilize after 14 
days while the P depletion curve still showed an increasing trend until 21 days. Smaller or 
slower depletions of both Ca and P were observed for CH-fibers/pH 5 during the first two 
weeks. However after that initial period certain acceleration is noticed in both ions 
depletion. It is here suggested that the pore walls collapse illustrated in Figure 5-21(d) 
might have contributed for an enhancement of Ca and P removal from SBF solution. These 
results also indicate that CH-fibers/pH 2 promote faster Ca and P SBF ions consumption. 
However this tendency may be altered by polymer degradation which seems to start earlier 
for scaffolds prepared from CH solutions pH5.    
Besides their different stabilization tendencies of Ca and P SBF concentration, it is 
also evident that depending on the CH solution pH, pH 2 and pH 5, different ∆Ca/∆P are 
observed. In CH-fibers/pH 2, the ∆Ca/∆P value after 21 days is close to 1.85 (∆wt /∆wt) 
or 1.4 (∆mol/∆mol) while in CH-fibers/pH 5 is close to 3.90(∆wt/∆wt) or to 2.9 
(∆mol/∆mol). These values also qualify the bioactivity difference between the scaffolds 
prepared at different pH, as already confirmed by XRD and FTIR (Figure 5-22 and Figure 
5-23). In CH-fibers/pH 2, the value of ∆Ca/∆P (1.4) is below the ratio of stoichiometric  
HAs (Ca/P= 1.6-1.7) while in CH-fibers/pH 5, the value of ∆Ca/∆P (2.90) indicates a 
different bioactivity in which the process of P absorption is delayed. The obtained curves 
anticipate that longer times will be required for CH-fibers/pH 5 if a value ∆Ca/∆P 
approaching that of stoichiometric HA is desired.  
In the case of CH-fibers/pH 2, the as prepared scaffold contains brushite (XRD in 
Figure 5-15 A). After 21 days of SBF immersion (XRD in Figure 5-22 A), the peak of 
brushite has disappeared thus indicating that its dissolution and possible recrystallization 
as a different CaP type. It is known that acidic CaP, like brushite, is not stable at pH values 
above 6. This reason explains why in SBF (pH ~7), brushite transforms into a more stable 
CaP72. Zhang and Zhang10 studied the bioactivity of β-TCP and glass reinforced chitosan 
composite scaffold and monitored the variations of Ca and P concentration during the first 
day prior to immersion. The results revealed that Ca and P concentrations increased due to 
dissolution of glass and β-TCP occurred during the first 20hours. Further observation 
showed the Ca and P concentrations decreased which indicated the formation of apatitic 
layer in the scaffold. 
As explained before, preparing the scaffolds at pH 2 turned out to dissolve some 
amount of HA fibers giving place to brushite precipitation during the later freezing step. 
(section 5.2.2.). The existing brushite in the scaffold CH-fibers/pH 2 underwent dissolution 
and precipitation during SBF immersion. The CaP re-precipitation will originate smaller 
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particles as compared to the original HA fibers. Compared to CH-fibers/pH 5, in which 
only HA fibers (in the size of 50-200µm) are present in the scaffold, the existence of other 
smaller sized precipitates in CH-fibers/pH 2 is though to offer more nucleation sites for 
apatite formation. As mentioned by Alves et al.73, smaller sized bioactive particles which 
reinforce in the composite enhance osteoblast proliferation and differentiation and thus 
further enhance biomineralization process.       
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5.3.Drug-Loaded Composite Scaffold 
 
A study of the chitosan based scaffolds prepared in this work for the application of 
drug delivery system was carried out. HA granules either loaded or unloaded with 
dexamethasone were prepared in the laboratory and futher mixed with chitosan solution. 
Dexamethasone used as a model drug in this present study is one kind of anti inflammatory 
drug6. It is widely used in bone engineering application; in osteogenic media to direct the 
differentiation of stem cells towards the osteogenic lineage74, 80. Drug delivery study on 
this system was aimed to design locally the controlled release of DEX in order to 
effectively support the bone ingrowth.   
5.3.1. Physicochemical Characterization 
Figure 5-25 shows the hydroxyapatite-dexamethasone (HA-DEX) and HA granules 
prepared by spray drying. Both microspheres have similar appearance, with no clear 
details information related to dexamethasone location or appearance in the microsphere. 
Both types of microspheres were used for the preparation of chitosan based composites 
loaded with DEX as a model drug. The as prepared scaffolds by freeze-drying chitosan 
solutions with HA and HA-DEX granules, were subsequently immersed without any 
rehydration process (ethanol treatment) in PBS solution for assessing the DEX release 
behavior. 
 
 
Figure 5-25 HA-DEX granules (top); pure HA granules (bottom) prepared by spray drying 
 The macroscopic observation of the scaffolds allowed verifying that they swelled 
and suffered dissolution for the drug delivery test.
results of other authors80 
The morphologies of drug
and after 7 days of immersion in PBS solution are shown in 
micrographs it can be observed the dissolution of chitosan on the wall structure of the 
scaffold as prepared (prior to 7 days immersion).
Figure 5-26 Wall appearance of drug
(A) and after 8 days of PBS immersion (
 
5.3.2. Drug Release Test
As mentioned in literature review (section 
morphologies can be used as drug carriers for the sustained release of a 
There are different possibilities of loading the drug in a composite scaffold: (1) by direct 
mixing all the components, (2) by loading the drug in one of the components and mixing it   
with the other components or (3) by impregnating or 
the drug75.  
In the present study, three 
(1) pure HA granules and DEX were added to CH solution; (2) DEX
were added to CH solution without any additi
additional DEX added to CH solution. A schematic illustration of these 3 methods is 
shown in Figure 5-27. In terms o
the drug amount corresponding either to procedure 1 or to procedure 2. The HA granules 
(Figure 5-25) used in the experiments were obtained in the laboratory
HA or HA-DEX suspensions. 
The in vitro DEX release profiles in PBS solution from the differently loaded 
composite scaffolds were followed during 30 days and are presented in 
figure, two types of curves are presented: (1) cum
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 Such behavior is in agreement with the 
-loaded chitosan based scaffolds (CH-HA-
Figure 5-26
  
-loaded chitosan based scaffold (prepared by procedure 2) before 
B); indicating polymer dissolution in the wall structure
 
2.1.5), different materials and 
therapeutic agent. 
coating a preformed structure with 
routes were followed to prepare DEX loaded scaffolds: 
-loaded HA granules 
onal DEX; and (3) procedure 2 with 
f DEX loaded amounts, procedure 3 uses the double of 
76
 by spray drying 
 
Figure 
ulative release percentage (A
 
 
DEX) before 
. From the 
 
 
5-28. In this 
) and (2) 
 absolute amount of released drug (
dependent on the drug loading procedure. 
Figure 5-27 Illustration of composite
Figure 5-28 Drug release profile of chitosan based scaffold based on the percentage cumulative release 
(A), and absolute amount of released drug (
A 
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B). The results clearly show that the release pattern is 
 
-DEX solution preparation and the as prepared scaffold
B) 
B 
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It can be observed for all the types of drug loaded scaffolds that an initial burst 
release occurred during the first 12 hours (Figure 5-28 and Figure 5-29). However, for 
longer release time, the scaffold prepared by procedure 1 showed the faster release in 
which after 2 days, the release curve started to stabilize. For procedures 2 and 3, the drug 
release seems to be rather delayed , being the release pattern of procedure 3 a more 
retarded one (Figure 5-28 A).   
 
Figure 5-29 Higher amplification for shorter release time from Figure 5-28 A 
The drug delivery profile from any delivery system depends on several factors: (1) 
the microstructure of the system, (2) the drug solubility, (3) the type of bond between the 
drug and the matrix, and (4) the mechanism of degradability of the matrix (if existing)77. 
From the point of view of polymer carriers, three main possible mechanisms are available 
for drug deliver: diffusion controlled, solvent-activation (swelling-osmotically controlled) 
and controlled by biodegradability (chemically-controlled)78. In the present study, the 
scaffolds were seen to degrade superficially (Figure 5-26 (b)). This indicates that besides 
diffusion, the biodegradability of the chitosan scaffold will be also contributing to the drug 
delivery. 
In the procedure 1, the initial burst release accounts for almost all the released 
drug. As the drug was dissolved directly in the composite suspension (CH + HA 
microspheres), most of the drug remained probably located in polymer matrix sites with 
easy access to the release medium. Conversely, using DEX-HA loaded granules 
(procedure 2 or 3) resulted in a less accessible location of the drug to the release medium. 
The drug loaded into the granules has now to diffuse through the granules and then 
through the polymer matrix before reaching the release medium. It can thus be considered 
that the closer to polymer matrix surface, the faster is the release. This is supposed to be 
the case of procedure 1 which showed the fastest drug release, with  approximately ~80% 
of the DEX being released in less than 2days.  
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Furthermore the initial burst release during the first few hours exhibited by all the 
scaffolds indicates that all scaffolds possess a certain amount of drug located in the near 
surface region, including the scaffold prepared by procedure 2. For this one, even though 
the drug was loaded only into the HA granules, there is a probability that a certain amount 
of DEX diffused to the chitosan solution before freeze drying and then precipitated within 
the polymer matrix during freezing. Such behavior indeed decreased the effectiveness of 
drug loading into HA granules.  Regarding the procedure 3, the addition of a certain 
amount of DEX to the chitosan solution decreases DEX concentration gradients  
throughout the whole system and thus minimizes the DEX diffusion out from the HA 
granules into the chitosan solution. By applying this method, the DEX concentration inside 
the HA granules is likely maintained and the diffusion from granules to chitosan solution 
minimized. This is confirmed by the curves in figure 5-27 (B) which show that the initial 
burst release in procedure 1 and 3 are essentially the same. This initial burst reflects the 
delivery of equivalent amounts of DEX existing within the polymer matrix which 
correspond to the same M mg of DEX dissolved in the CH solutions of both cases.  
Compared to procedure 1, both procedures 2 and 3 show the ability to retard the 
drug release. The scaffold prepared using procedure 2 showed an initial burst drug release 
of about ~45% of the total loaded drug during the first 12 hours (Figure 5-29), followed by 
a slower release until 80% during the remaining 30days (Figure 5-28 (A)). The results also 
show that preparing the composite scaffolds by procedure 3,i.e. by adding an extra amount 
of DEX to the CH solution, allowed to reduce the initial burst release to ~30%, thus 
enabling a larger amount of DEX to be released slower during the remaining period. This 
fact demonstrates that the drug initially added to the chitosan solution succeeded to keep 
the drug confined to the granules during the initial period of drug release thus slowing 
down the overall release rate.  
Fitting the initial burst release to Fickian diffusional release equation of the type:  
   


= 

       (5.3) 
where  is the amount of DEX released at t time, ∞is the total released amount 
at infinite time, t is the release time, k is a constant, and n is the diffusional exponent, it 
was observed that the initial burst release data corresponding to the release time ~10hours 
fit well the equation. The value obtained for n was close to ~0.42. This value of n is close 
to n = 0.5, which indicates a diffusion controlled release74, 79. It is thus suggested that 
diffusion controlled drug release occurs in all the prepared scaffolds during the initial 
release periods. Further studies are required to explain the mechanism applying to longer 
release times. 
The drug loading methods of chitosan scaffolds used in the present work improved 
the DEX sustained release ability. Duarte et al.80 prepared chitosan scaffold loaded with 
dexamethasone using supercritical impregnation, and the result showed that almost 90% of 
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the loaded drug was released after 2 hours. Chitosan composite scaffold with β-TCP and 
glass which were loaded by gentamicin sulphate via 48h of soaking showed initial burst 
releasing ~80% of the drug during 2 days and followed by slower release until ~20days7. 
Comparing with these two methods, it is worthy to mention the advantages of loading the 
drug into HA microspheres and further inserted them into the chitosan solution before 
freeze-drying (both procedure 2 and 3).  The results pointed out that those scaffolds were 
able to retard the drug release evidencing a sustained release profile of DEX, thus 
suggesting their potential to be used as controlled drug release system. 
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Chapter 6  
Conclusions & Recommendations 
 
A comprehensive study on chitosan based scaffolds for bone regeneration has been 
carried out in the present work. Different types of chitosan based scaffolds were prepared 
with different composition and under different conditions. HA fibers and monetite thin 
platelets were obtained by a precipitation method. These two types of CaP particles as well as 
a mixture of them were used as reinforcing elements of chitosan scaffolds. HA granules 
(loaded or unloaded with DEX) prepared by spray-drying were also used to load the scaffolds 
with DEX. Microstructure characteristics (pore size, porosity and interconnectivity), crystal 
phase composition, mechanical properties, bioactivity, and drug delivery performance of the 
produced scaffolds were studied.  
 
CaP particles precipitation 
HA fibers with a size in the range of 50-150µm were successfully produced by a 
precipitation method reported by Aizawa et al.38 and Zhang et al.39, in moderately acidic 
solution. Three main stages were identified in the precipitation (1) formation of platelet 
shaped monetite, (2) formation of fibers-like OCP, and (3) transformation of fibers-like OCP 
crystal into HA. The fiber morphology was defined in the first 24 hours of refluxing at 80ºC 
while increasing refluxing temperature to 90ºC ensured the transformation of OCP into HA. 
It was also demonstrated that modifying Zhang method by anticipating the 90ºC refluxing 
does enable to reduce the time required for obtaining HA fibers.  
 
Chitosan based Scaffolds 
Highly interconnected macroporous scaffolds with pore sizes in the range of 50-
300µm, interconnectivity around 91-98.5%, and porosity higher than 80% were produced by 
freeze-drying. Three dimensional chitosan based scaffold loaded either with HA fibers, or 
with monetite platelets or a mixture of both were characterized in terms of microstructure, 
crystal phase composition, mechanical and bioactive behaviors and compared to pure 
chitosan scaffold. The pH of chitosan solution, the freezing temperature during TIPS and the 
type of loaded calcium phosphate particle were confirmed to have a significant influence in 
the properties of the obtained scaffolds. These variables showed to play an important role in 
defining the scaffold microstructure. Larger pores were normally obtained when using higher 
freezing temperature, higher pH CH solutions and by HA fibers loading (pH 5).  
The mechanical properties of the scaffolds were seen to be highly dependent on pore 
size and on the type of reinforcement.  Low pH values and freezing temperatures resulted in 
scaffolds of smaller pore and hence with better mechanical properties. Conversely, high pH 
value and freezing temperature resulted in larger pore but lower mechanical properties. The 
morphology of the reinforcing-particles was also a critical variable. Monetite thin platelets 
displayed a better reinforcing ability as compared to HA fibers, being this effect attributed to 
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the irregular and smaller sized platelet shape which allowed a better bonding with polymer 
matrix. From the point of view of bioactivity, chitosan composite scaffold loaded with HA 
fibers exhibited enhanced bioactive response as compared to pure chitosan. Continuous 
variation of Ca and P concentrations in SBF solution during scaffolds soaking indicated 
deposition of apatite layer in the materials. This behavior was not observed in pure chitosan 
scaffold. 
Some experimental conditions combinations were found appropriated for obtaining 
scaffolds which porosity, pore size, interconnectivity and mechanical properties point out a  
potential applicability in bone tissue engineering, CH-fibers/pH 2 frozen at -15oC 
demonstrated the best bioactivity and mechanical properties (compressive modulus: 
2.58Mpa, compressive strength: 0.18Mpa) while displaying an average pore size of ~136µm.  
Other produced scaffolds were found to have larger pore sizes such as CH-fibers/pH 5 frozen 
at -15oC (~152µm) and CH-fibers/pH 5 frozen at -196oC (~190µm) but lower mechanical 
properties. CH-monetite/pH 5 frozen at 0oC showing the second best mechanical properties 
(compressive modulus: 0.7-0.87Mpa, compressive strength: 0.07-0.11Mpa) with an average 
pore size (~170µm) is also worthy mentioning. These pore size values are already close to the 
size required (200-400µm) for good cell proliferation. However, from the point of view of 
mechanical properties, the obtained scaffolds still need to be improved. 
 
Chitosan based Scaffolds DDS 
Loading dexamethasone as a drug model into HA granules and inserted them further 
in chitosan scaffold was proved to be a good strategy to retard the drug release. Three 
different methodologies of drug loading into to the scaffolds were confirmed to affect 
significantly the drug release rate. Immobilizing the drug in HA granules by spray drying 
before combining with the chitosan solution demonstrated slower release as compared to 
mixing directly the drug with the CH solution. An even slower release rate could be obtained 
by adding DEX to the chitosan solution in order to minimize DEX concentration gradients: 
25% of DEX was released during the first 14hours being followed by a slow release of DEX 
until 80% during the remaining 30days.  This method showed to provide a slower release rate 
as compared to other reports   
 
This study underscores the chitosan based scaffold as a potential scaffold for bone 
regeneration and drug delivery system.  
 
Recommendations for Future Work 
The results obtained in the present work revealed some needs of further studies 
aiming to clarify the following issues: 
1. Freezing temperature during TIPS was shown to be a critical variable for determining  the 
pore structure which in turns determines the mechanical properties. However freezing at -
196ºC is though to have a potential for pore orientation which was not exploited in the 
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present work. It is thus suggested to test sufficiently low freezing temperatures combined 
with different freezing methologies for exploiting the method potentialities for pore 
alignment. 
2. The effects of increasing loads of CaP particles in CH scaffolds need to be investigated 
for assessing its effect on both the scaffold pore size and mechanical properties. 
3. Drug release studies with various drug concentrations should be undertaken for assessing 
the active mechanisms during drug release for longer times, It is expected that such 
studies might contribute to identify the scaffold parameters that rule DEX release.   
4. Biocompatibility test (cell culture tests) should be carried out in order to study the cell 
response (attachment and or proliferation).dependence on the scaffolds characteristics.  
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APPENDICES 
  
Appendix 1 – CH Based Composite Scaffolds 
Table A-1 Average pore size (µm) from SEM and µCT, interconnectivity, porosity of the 
prepared scaffolds  
 
pH 2 pH 2 loaded pH 5 pH 5 loaded 
 
HA 
Fibers  
HA 
Fibers 
Monetite 
Powder 
Mixture 
(HA fibers + 
monetite 
powder) 
-
196oC 
Pore Size  
SEM: 
57.9±10 
- 
Pore Size 
SEM: 
222±91 
Pore size µCT: 
190 
porosity: 80.6% 
intercn: 91.6% 
- - 
-15oC 
Pore Size 
SEM: 
127±16 
Pore Size  
SEM: 99.5±21 
µCT: 136 
porosity: 
90.7% 
intercn: 98% 
Pore Size  
SEM: 
130±35 
Pore Size  
SEM: 136.5±23 
µCT: 152 
porosity: 90.7% 
intercn: 98.5% 
- 
Pore Size 
SEM: 
129.24±24 
0C Pore Size 
SEM: 
154±37 
- 
Pore Size  
SEM: 
166±26 
 
Pore Size 
SEM: 
157±31 
- 
Table A-2 Mechanical properties of the prepared scaffolds (M: Compressive Modulus; 
S: Compressive Strength in MPa) 
 pH 2 pH 2 loaded pH 5 pH 5 loaded 
 HA 
Fibers 
 HA 
Fibers 
Monetite 
Powder 
Mixture 
(HA fibers + 
monetite 
powder) 
-196oC - - - M= 0.616±0.10 
S= 0.112±0.028 
- - 
-15oC M=0.2 
S=0.02 
M= 2.58±0.34 
S= 0.158±0.022 
M=0.65 
S=0.025 
M=0.79±0.4 
S=0.048±0.007 
- M=0.64±0.16 
S=0.079±0.007 
0C - -  - M=1.1±0.35 
S=0.09±0.01 
- 
Table A-3 Geometrical density (g/cm3) of the prepared scaffolds  
 
pH 2 pH 2 loaded pH 5 pH 5 loaded 
 
HA 
Fibers  
HA 
Fibers 
Monetite 
Powder 
Mixture 
(HA fibers + 
monetite 
powder) 
-196oC - - 0.0524 0.0714 - - 
-15oC 0.03686 0.05074 0.0541 0.0628 - 0.0689 
0C - - - - 0.06167 - 
Appendix 2 – Drug Release Test 
Drug Release Test 
Standard Curve of DEX 
Standard curve was made by preparing DEX solution in several concentrations; such 
as 5, 10, 20, and 30 µg/mL in PBS solution. The absorbance was observed with UV-Vis 
spectroscopy and noted as follows: 
Table A-4 Absorbance of DEX solution in PBS 
[C] µg/ml Absorbance 
0 0 
5 0.195 
10 0.372 
20 0.73 
30 1.078 
 
From the absorbance data written above, curve was built and line equation was made, 
as shown in the figure below: 
 
Figure A-1 Standard Calibration Curve for DEX solution in PBS 
 
With: y is the absorbance; x is the concentration in (µg/mL). 
Based on the linear equation above, for one known absorbance (from UV Vis spectroscopy), 
the concentration can be calculated as follows: 
 =
 − 0.0097
0.0358
   	 
 
Appendix 2 – Drug Release Test 
Drug Release Test 
Table A-5 CH/HA Composite Solution/Suspension for DDS 
 Procedure 1 Procedure 2 Procedure 3 
2%wt CH solution 10 g 10 g 10 g 
HA granules 100 mg pure HA 
granules 
100 mg spray dried 
HA-DEX granules 
100 mg spray dried 
HA-DEX granules 
Additional DEX - - 10 mg 
 
Procedure 1 
Amount of DEX in freeze-dried scaffold: 
Mass of freeze-dried scaffold is assumed to be chitosan & HA granules  
# 10g CH composite solution contains 2%wt chitosan (0.2g) and 1%wt pure HA granules (0.1g). 
# Amount of added drug = 10mg/10 g CH composite solution 
# Amount of DEX in freeze-dried scaffold = 10mg/(0.2g CH + 0.1g HA + 10mg DEX) 
 = 10mg DEX/0.31g freeze-dried scaffold. 
 
Percentage of drug release: 
# Drug release = Ct/Co x 100% 
# Ct = concentration of DEX at certain time (µg/mL)  
 Ct (µg/mL) = (abs-0.0097)/0.0358  
 Abs = aborbance obtained from UV-Vis analysis 
# Co = concentration of DEX if 100% drug release (µg/mL) 
 Co (µg/mL) = (10mg/0.31g) x mass of scaffold x1000 / 10mL (PBS) 
   
Table A-6 DDS Release Test – Procedure 1 
No Mass 
Scaffold 
(g) 
Time Absorbance Drug Release 
(%) 
(µg/mL)/mg of 
scaffold 
1 0.0106 5 min 0.141 10.72 0.346 
2 0.0153 10 min 0.163 8.67 0.279 
3 0.0144 60 min 0.300 17.57 0.567 
4 0.0158 3h 0.484 25.99 0.838 
5 0.0165 7h 0.827 42.89 1.383 
6 0.0108 15h 30min 0.738 58.39 1.883 
7 0.0178 25h 1.106 53.33 1.720 
8 0.0145 2days 1.294 76.69 2.474 
9 0.0177 4days 1.610 78.290 2.525 
10 0.0163 7days 1.437 75.823 2.445 
 
Appendix 2 – Drug Release Test 
Procedure 2 
Amount of DEX in freeze-dried scaffold: 
Mass of freeze-dried scaffold is assumed to be chitosan & HA granules  
# 10g CH composite solution contains 2%wt chitosan (0.2g) and 1%wt pure HA granules (0.1g). 
# Amount of drug = in HA granules (10%wt) = (10% . 0.1g) = 10mg 
# Amount of DEX in freeze-dried scaffold = 10mg/(0.2g CH + 0.1g HA) 
 = 10mg DEX/0.30g freeze-dried scaffold. 
 
Percentage of drug release: 
# Drug release = Ct/Co x 100% 
# Ct = concentration of DEX at certain time (µg/mL)  
 Ct (µg/mL) = (abs-0.0097)/0.0358  
 Abs = aborbance obtained from UV-Vis analysis 
# Co = concentration of DEX if 100% drug release (µg/mL) 
 Co (µg/mL) = (10mg/0.30g) x mass of scaffold x1000 / 10mL (PBS)   
 
Table A-7 DDS Release Test – Procedure 2 
No Mass 
Scaffold 
(g) 
Time Absorbance Drug Release 
(%) 
(µg/mL)/mg of 
scaffold 
1 0.0147 10min 0.202 10.96 0.365 
2 0.0114 60min 0.323 23.02 0.767 
3 0.0149 2hours 0.498 27.46 0.915 
4 0.0136 3hours 0.525 31.75 1.058 
5 0.0168 5hours 0.657 32.28 1.076 
6 0.0108 14hours 0.621 47.43 1.581 
7 0.0104 1day 0.597 47.32 1.577 
8 0.0142 4days 0.786 45.81 1.527 
9 0.0099 8days 0.635 52.92 1.764 
10 0.0108 30days 0.968 74.35 2.478 
 
Procedure 3 
 
Amount of DEX in freeze-dried scaffold: 
Mass of freeze-dried scaffold is assumed to be chitosan & HA granules  
# 10g CH composite solution contains 2%wt chitosan (0.2g) and 1%wt pure HA granules (0.1g). 
# Amount of drug 
  = in HA granules (10%wt) + additional DEX 10mg/10 g CH composite solution 
 = (10% . 0.1g) + (10mg) = 20mg 
# Amount of DEX in freeze-dried scaffold = 20mg/(0.2g CH + 0.1g HA + 10mg DEX) 
Appendix 2 – Drug Release Test 
 = 20mg DEX/0.31g freeze-dried scaffold. 
 
Percentage of drug release: 
# Drug release = Ct/Co x 100% 
# Ct = concentration of DEX at certain time (µg/mL)  
 Ct (µg/mL) = (abs-0.0097)/0.0358  
 Abs = aborbance obtained from UV-Vis analysis 
# Co = concentration of DEX if 100% drug release (µg/mL) 
 Co (µg/mL) = (20mg/0.31g) x mass of scaffold x1000 / 10mL (PBS) 
 
Table A-8 DDS Release Test – Procedure 3 
No Mass 
Scaffold 
(g) 
Time Absorbance Drug Release 
(%) 
(µg/mL)/mg of 
scaffold 
1 0.0148 10min 0.234 6.56 0.423 
2 0.0133 60min 0.329 10.39 0.670 
3 0.0118 2hours 0.536 19.31 1.245 
4 0.0145 3hours 0.594 17.44 1.125 
5 0.014 5hours 0.688 20.97 1.353 
6 0.0128 14hours 0.756 25.24 1.628 
7 0.012 1day 0.857 30.57 1.972 
8 0.0145 4days 1.266 37.51 2.420 
9 0.0139 8days 1.358 41.99 2.709 
10 0.0117 30days 2.16 79.57 5.133 
 
 
 
 
 
